Heterocyclic compounds as fgfr inhibitors and uses thereof
By developing heterocyclic compounds that can selectively inhibit FGFR, the tumor problem caused by overactivation of the FGFR signaling pathway has been solved, and effective killing of related tumor cells has been achieved.
Patent Information
- Application Number
- CN202280024337.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-07
- Filing Date
- 2022-04-01
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-04-01
AI Technical Summary
In existing technologies, overactivation of the FGFR signaling pathway leads to tumor development and progression, and there is a lack of effective targeted therapies.
A class of heterocyclic compounds is provided that can selectively inhibit FGFR proteins, affecting their biological functions, and can be used to prepare for the prevention or treatment of FGFR-related diseases.
This heterocyclic compound can effectively inhibit FGFR activity and has potential anti-tumor effects, especially killing tumor cells associated with abnormal FGFR activation, such as gastric cancer, intrahepatic cholangiocarcinoma, endometrial cancer, and bladder cancer.
Smart Images

Figure CN117222640B_ABST
Abstract
Description
[0001] Cross-references to related applications
[0002] This application claims the benefit and priority of the following two Chinese invention patent applications, the entire contents of which are incorporated herein by reference:
[0003] Patent application No. 202110380922.X, filed with the China National Intellectual Property Administration on April 3, 2021; and
[0004] Patent application No. 202210224490.8 was filed with the China National Intellectual Property Administration on March 7, 2022. Technical Field
[0005] This invention belongs to the field of pharmaceutical technology and relates to heterocyclic compounds of FGFR inhibitors, their preparation methods, and applications. Background Technology
[0006] FGFR (Fibroblast Growth Factor Receptor) is a transmembrane receptor tyrosine kinase, with the family mainly consisting of four members: FGFR1, 2, 3, and 4. Upon binding to its ligand FGF (fibroblast growth factor), FGFR induces receptor dimerization, leading to phosphorylation of tyrosine residues in the kinase domain and activation of the receptor. Activated FGFR then further activates downstream signaling pathways such as RAS / RAF, PI3K / AKT, JAK / STAT, and PLCγ, participating in the regulation of multiple processes including cell proliferation, apoptosis, migration, repair of damaged tissues, and angiogenesis. Under normal physiological conditions, the FGFR signaling pathway is strictly regulated and remains at a weak activation level. However, excessive activation often leads to tumor development and progression. The molecular mechanisms of abnormal FGFR activation mainly include: 1) gene amplification; 2) gene mutation; and 3) gene fusion caused by gene translocation. For example, FGFR2 gene amplification occurs in gastric cancer (5-10%), FGFR2 gene translocation occurs in intrahepatic cholangiocarcinoma (14%), and FGFR2 gene mutation occurs in endometrial cancer (12-14%). FGFR3 gene abnormalities are most common in bladder cancer, including gene mutations (60-80% of non-muscle-invasive bladder cancer and 15-20% of muscle-invasive bladder cancer), gene translocations (3-6%), and gene amplification (incidence not reported); the second most common is myeloma, with 15-20% of myeloma patients having FGFR3 gene translocations. Some of these FGFR gene abnormalities have been shown to be associated with poor patient prognosis.
[0007] Given the importance of the FGFR signaling pathway in cancer treatment, targeted therapy against the FGFR signaling pathway has become a research hotspot in the field of cancer treatment in recent years. This patent application discovers a class of heterocyclic compounds that can selectively inhibit FGFR proteins, such as FGFR2, and have a killing effect on related tumor cells. Summary of the Invention
[0008] This invention provides a class of heterocyclic compounds, their stereoisomers, and pharmaceutically acceptable salts. These compounds can inhibit the activity of FGFRs, thereby affecting their biological function.
[0009] Specifically, the present invention provides a compound of formula (I), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
[0010]
[0011] (I)
[0012] X and Z are each independently selected from CR 9 Or N;
[0013] W is selected from O or C (=O);
[0014] Y is selected from C(=O), NHC(=O), C(=O)NH, N(CH3) or bonds;
[0015] Ring A is selected from 5-10 membered heteroaryl or 5-10 membered heterocyclic group;
[0016] Ring B is selected from C6-C 10 Aryl, 5-10 heteroaryl or C3-C 10 Cyclic hydrocarbon group;
[0017] E is selected from C3-C 10 Cyclic hydrocarbon group, C6-C 10 Aryl, 3-12 membered heterocyclic or 5-12 membered heteroaryl, wherein the C3-C 10 Cyclic hydrocarbon C6-C 10 Aryl, 3-12 heterocyclic or 5-12 heteroaryl, optionally bound by one or more R 1a replace;
[0018] R 1a Independently selected from halogens, CN, NH2, OH, C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, C1-C6 alkoxy, -S(=O)-C1-C4 alkyl, -S(=O)2-C1-C4 alkyl, -S(=O)(=NR) 8a )R 8b -N=S(=O)R 8a R 8b-NR 8a R 8b -C(=O)NR 8a R 8b or -NR 7 C(=O)R 8b The C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, C1-C6 alkoxy, -S(=O)-C1-C4 alkyl or -S(=O)2-C1-C4 alkyl may optionally be substituted by one or more groups independently selected from halogen, OH, C1-C3 alkoxy or CN;
[0019] R 1 Selected from -CN and -(CH2) q CN、-C≡CR 5 -C(=O)C≡CR 5 -C(=O)CR 6 =C(R 5 )2、- R 7 C(=O)CH=C(R 5 )2、-NHC(=O)CR 6 =C(R 5 )2、-R 7 NHC(=O)CH=C(R 5 2. -NHC(=O)C≡CR 5 -S(=O)CR 6 =C(R 5 )2、-S(=O)2CR 6 =C(R 5 )2、-NHS(=O)CR 6 =C(R 5 )2、-NHS(=O)2CR 6 =C(R 5 )2、-NR 6 C(=O)CR 6 =C(R 5 )2 or NHC(=O)R 5 ;
[0020] R 5 Independently selected from H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cyclic hydrocarbon, 3-12 membered heterocyclic group or C6-C 10 aryl, wherein the C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cyclic hydrocarbon, 3-12 membered heterocyclic group or C6-C 10 The aryl group is optionally bounded by one or more R groups. 5a replace;
[0021] R 5aIndependently selected from halogens, CN, N(R) 5b 2, OH, NO2, C3-C8 cycloalkyl or 3-12 membered heterocyclic groups;
[0022] R 5b Independently selected from H or C1-C6 alkyl groups;
[0023] R 6 Selected from H, CN, halogens, or C1-C6 alkyl groups;
[0024] R 7 Selected from C1-C6 alkylene groups, C3-C8 cycloalkylene groups, or 3-12 membered heterocyclic groups;
[0025] R 2 Selected from H, NH2, C1-C6 alkyl, OH or halogen;
[0026] R 3 It is independently selected from halogens, CN, NH2, OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy or C3-8 cycloalkyl;
[0027] R 4 Independently selected from halogens, CN, NH2, OH, NO2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3-10 membered heterocyclic groups, -C(=O)R 8a -C(=O)OR 8a -NR 8a R 8b -C(=O)NR 8a R 8b or -NR 7 C(=O)R 8b The C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or 3-10 membered heterocyclic group is optionally surrounded by one or more R groups. 4a replace;
[0028] R 4a Independently selected from halogens, CN, NH2, OH, or C1-C6 alkyl groups;
[0029] R 8a R 8b Each is independently selected from H, halogen, CN, NH2, OH, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkyl;
[0030] R 9 Selected from H, CN, OH, NH2, -NHR 10-NH-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy or C3-C8 cycloalkyl, wherein the C1-C6 alkyl, -NH-C1-C6 alkyl, C1-C6 alkoxy or C3-C8 cycloalkyl is optionally surrounded by one or more R 10 replace;
[0031] R 10 Independently selected from halogens, NH2, C3-C8 cycloalkyl groups, 3-10 membered heterocyclic groups, C6-C 10 aryl or 5-10 membered heteroaryl, wherein the NH2, C3-C8 cycloalkyl, 3-10 membered heterocyclic, C6-C 10 aryl or 5-10 heteroaryl groups are optionally surrounded by one or more R groups. 11 replace;
[0032] R 11 Independently selected from C1-C6 alkyl, halogen, C1-C6 alkoxy, C3-C8 cycloalkyl or 3-10 heterocyclic groups, wherein the C1-C6 alkyl, C3-C8 cycloalkyl or 3-10 heterocyclic group is optionally substituted with C1-C6 alkyl, halogen, OH, -NH-C1-C6 alkyl, -N(C1-C6 alkyl)2;
[0033] n and m are each independently selected from 0, 1, 2 or 3;
[0034] q is selected from 1, 2, or 3.
[0035] In some implementations, ring A is selected from 5-10 membered heteroaryl groups.
[0036] In some implementations, ring A is selected from 5-6 membered heteroaryl groups.
[0037] In some implementations, ring A is selected from 5-6 membered heteroaryl or 5-6 membered heterocyclic groups.
[0038] In some embodiments, ring A is selected from pyrimidinyl, pyridinyl, or tetrahydropyrroleyl.
[0039] In some embodiments, ring A is selected from pyrimidinyl or tetrahydropyrroleyl.
[0040] In some embodiments, ring A is selected from pyridinyl or pyrimidinyl.
[0041] In some implementations, ring A is selected from pyrimidinyl groups.
[0042] In some implementations, ring B is selected from C6-C. 10 Aryl or 5-10 heteroaryl compounds.
[0043] In some implementations, ring B is selected from C6-C. 10 Aryl or C3-C 10Cyclic hydrocarbon group.
[0044] In some embodiments, cyclo B is selected from phenyl or cyclohexenyl.
[0045] In some implementations, ring B is selected from phenyl.
[0046] In some implementations, W is selected from O.
[0047] In some implementations, Y is selected from C(=O), NHC(=O), C(=O)NH or bonds.
[0048] In some implementations, Y is selected from N(CH3) or bonds.
[0049] In some implementations, Z is selected from CR 9 .
[0050] In some embodiments, E is selected from C3-C6 cyclic hydrocarbon groups, C6-C 10 aryl, 3-10 membered heterocyclic or 5-10 membered heteroaryl, wherein the C3-C6 cyclic hydrocarbon group, C6-C 10 Aryl, 3-10 heterocyclic or 5-10 heteroaryl are optionally R 1a replace.
[0051] In some implementations, E is selected from C6-C. 10 Aryl, 3-10 membered heterocyclic or 5-10 membered heteroaryl, wherein the C6-C 10 Aryl, 3-10 heterocyclic or 5-10 heteroaryl are optionally R 1a replace.
[0052] In some implementations, E is selected from C6-C. 10 Aryl, 3-10 membered heterocyclic or 5-6 membered heteroaryl, wherein the C6-C 10 Aryl, 3-10 heterocyclic or 5-6 heteroaryl groups are optionally R 1a replace.
[0053] In some implementations, E is selected from R. 1aThe following groups are substituted: phenyl, pyranyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thiopheneyl, pyrroloyl, pyrazolyl, thiazolyl, imidazolyl, benzofuranyl, benzimidazolyl, benzothiopheneyl, benzoxazolyl, benzothiazolyl, indolyl, quinolinyl, isoquinolinyl, tetrahydropyrroloyl, tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2-pyridoneyl, 2-piperazinoneyl, azacyclobutyl, 1,4-diazacycloheptyl, bicyclo[1.1.1]pentyl, 2,7-dicyclohexaneyl, cyclo[1.1.1]pent ... Azaspirocyclic[4.4]nonyl, 2,8-diazaspirocyclic[4.5]decyl, 2,7-diazaspirocyclic[3.5]nonyl, 2,6-diazaspirocyclic[3.5]nonyl, 2,6-diazaspirocyclic[3.3]heptyl, 2,6-diazaspirocyclic[3.4]octyl, 2,5-diazaspirocyclic[3.4]octyl, 4,7-diazaspirocyclic[2.5]octyl, 2,5-diazabicyclo[2.2.1]heptyl, 5,8-diazaspirocyclic[3.5]nonyl, 3,8-diazabicyclo[3.2.1]octyl or dihydropyrrole.
[0054] In some implementations, E is selected from R. 1a The following groups are substituted: phenyl, pyranyl, pyridyl, pyrimidinyl, pyridazinyl, furanyl, thiopheneyl, pyrroloyl, pyrazolyl, thiazolyl, imidazolyl, benzofuranyl, benzimidazolyl, benzothiopheneyl, benzoxazolyl, benzothiazolyl, indolyl, quinolinyl, isoquinolinyl, tetrahydropyrroloyl, tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2-pyridoneyl, 2-piperazinyl Azinone, azirone, 1,4-diazaspiroheptanyl, bicyclo[1,1,1]pentyl, 2,7-diazaspiro[4.4]nonyl, 2,8-diazaspiro[4.5]decyl, 2,7-diazaspiro[3.5]nonyl, 2,6-diazaspiro[3.5]nonyl, 2,6-diazaspiro[3.3]heptyl, 2,6-diazaspiro[3.4]octyl or 2,5-diazaspiro[3.4]octyl.
[0055] In some implementations, E is selected from R. 1aThe following groups are substituted: phenyl, pyridinyl, thiophene, pyrazolyl, imidazolyl, azacyclobutyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, tetrahydropyridinyl, cyclohexyl, cyclohexenyl, morpholinyl, 2-piperazinone, 2-pyridinone, 1,4-diazaspirocyclic heptyl, bicyclo[1,1,1]pentyl, 2,7-diazaspirocyclic[4.4]nonyl, 2,8-diazaspirocyclic[4.5]decyl, 2,7-diazaspirocyclic[3.5]nonyl, 2,6-diazaspirocyclic[3.5]nonyl, 2,6-diazaspirocyclic[3.3]heptyl, 2,6-diazaspirocyclic[3.4]octyl, 2,5-diazaspirocyclic[3.4] Octyl, 4,7-diazaspirocyclo[2.5]octyl, 2,5-diazabicyclo[2,2,1]heptyl, 5,8-diazaspirocyclo[3.5]nonyl, 3,8-diazabicyclo[3,2,1]octyl or dihydropyrrole.
[0056] In some implementations, E is selected from R. 1a The following groups may be substituted: phenyl, pyridinyl, thiophene, pyrazolyl, imidazolyl, aziridine, tetrahydropyrrolyl, piperidinyl, piperazinyl, tetrahydropyridinyl, cyclohexyl, cyclohexenyl, morpholinyl, 2-piperazinone, 2-pyridinone, 1,4-diazaspiroheptanyl, bicyclo[1,1,1]pentyl, 2,7-diazaspiro[4.4]nonyl, 2,8-diazaspiro[4.5]decyl, 2,7-diazaspiro[3.5]nonyl, 2,6-diazaspiro[3.5]nonyl, 2,6-diazaspiro[3.3]heptyl, 2,6-diazaspiro[3.4]octyl, or 2,5-diazaspiro[3.4]octyl.
[0057] In some implementation schemes, R 1a Independently selected from halogens, CN, NH2, OH, C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, C1-C6 alkoxy, -S(=O)-C1-C4 alkyl, -S(=O)2-C1-C4 alkyl, -S(=O)(=NR) 8a R 8b -N=S(=O)R 8a R 8b -NR 8a R 8b -C(=O)NR 8a R 8b or -NR 7 C(=O)R 8bThe C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, C1-C6 alkoxy, -S(=O)-C1-C4 alkyl or -S(=O)2-C1-C4 alkyl may optionally be substituted by one or more groups independently selected from halogen, OH or C1-C3 alkoxy.
[0058] In some implementation schemes, R 1a Independently selected from halogens, CN, NH2, OH, -NR 8a R 8b The C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, and C1-C6 alkoxy group are optionally substituted by one or more groups independently selected from halogen, OH, or C1-C3 alkoxy groups.
[0059] In some implementation schemes, R 1a The group is independently selected from halogen, CN, NH2, OH, C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, and C1-C6 alkoxy group, wherein the C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, and C1-C6 alkoxy group are optionally substituted by one or more groups independently selected from halogen, OH, or C1-C3 alkoxy group.
[0060] In some implementation schemes, R 1a Independently selected from halogens, -NR 8a R 8b The C1-C6 alkyl or C1-C6 alkoxy group is optionally substituted with one or more groups independently selected from halogen, OH, CN or C1-C3 alkoxy groups.
[0061] In some implementation schemes, R 1a It is independently selected from C1-C6 alkyl or C1-C6 alkoxy.
[0062] In some implementation schemes, R 1a It is independently selected from Cl, F, CH3, -OCH3, CF3, -N(CH3)2 or CH2CN.
[0063] In some implementation schemes, R 1a It is independently selected from CH3 or -OCH3.
[0064] In some implementation schemes, R 1 Selected from -CN and -(CH2) q CN, -C≡CH, -C(=O)C≡CR 5 -C(=O)CR 6 =C(R 5 )2、-R7 C(=O)CH=C(R 5 )2、-NHC(=O)CR 6 =C(R 5 )2、-R 7 NHC(=O)CH=C(R 5 2. -NHC(=O)C≡CR 5 -S(=O)CR 6 =C(R 5 )2、-S(=O)2CR 6 =C(R 5 )2、-NHS(=O)CR 6 =C(R 5 )2 or -NHS(=O)2CR 6 =C(R 5 )2.
[0065] In some implementation schemes, R 1 Selected from -C≡CR 5 -C(=O)C≡CR 5 -C(=O)CR 6 =C(R 5 )2、- R 7 C(=O)CH=C(R 5 )2、-NHC(=O)CR 6 =C(R 5 )2、-R 7 NHC(=O)CH=C(R 5 2. -NHC(=O)C≡CR 5 -S(=O)CR 6 =C(R 5 )2、-S(=O)2CR 6 =C(R 5 )2、-NHS(=O)CR 6 =C(R 5 )2、-NHS(=O)2CR 6 =C(R 5 )2、-NR 6 C(=O)CR 6 =C(R 5 )2 or NHC(=O)R 5 .
[0066] In some implementation schemes, R 1 Selected from -CN and -(CH2) q CN、-C≡CR 5 -C(=O)C≡CR 5 -C(=O)CR 6=C(R 5 )2、- R 7 C(=O)CH=C(R 5 )2、-NHC(=O)CR 6 =C(R 5 )2、-R 7 NHC(=O)CH=C(R 5 2. -NHC(=O)C≡CR 5 -NHS(=O)2CR 6 =C(R 5 )2、-NR 6 C(=O)CR 6 =C(R 5 )2 or NHC(=O)R 5 .
[0067] In some implementation schemes, R 1 Selected from -(CH2) q CN, -C≡CH, -C(=O)C≡CR 5 -C(=O)CR 6 =C(R 5 )2、-R 7 C(=O)CH=C(R 5 )2、-NHC(=O)CR 6 =C(R 5 )2、-R 7 NHC(=O)CH=C(R 5 2. -NHC(=O)C≡CR 5 or -NHS(=O)2CR 6 =C(R 5 )2.
[0068] In some implementation schemes, R 1 Selected from -C≡CR 5 -C(=O)C≡CR 5 -C(=O)CR 6 =C(R 5 )2、- R 7 C(=O)CH=C(R 5 )2、-NHC(=O)CR 6 =C(R 5 )2、-R 7 NHC(=O)CH=C(R 5 2. -NHC(=O)C≡CR 5 -NHS(=O)2CR 6 =C(R 5 )2、-NR 6 C(=O)CR6 =C(R 5 )2 or NHC(=O)R 5 .
[0069] In some implementation schemes, R 6 Selected from H, F, Cl, CN or CH3.
[0070] In some implementation schemes, R 6 Selected from H, F, CN or CH3.
[0071] In some implementation schemes, R 5 Independently selected from H, C1-C3 alkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl or C3-C6 cycloalkyl is optionally surrounded by one or more R 5a replace.
[0072] In some implementation schemes, R 5 Independently selected from H or C1-C3 alkyl groups, wherein the C1-C3 alkyl group is optionally surrounded by one or more R groups. 5a replace.
[0073] In some implementation schemes, R 5a Independently selected from halogens, CN, N(R) 5b )2 or 3-12 membered heterocyclic groups.
[0074] In some implementation schemes, R 5a Independently selected from halogens, CN, N(R) 5b )2 or 3-6 membered heterocyclic groups.
[0075] In some implementation schemes, R 5a Independently selected from N(R) 5b )2 or 3-6 membered heterocyclic groups.
[0076] In some implementation schemes, R 5a It is independently selected from halogen, CN, N(CH3)2, piperidinyl or morpholinyl.
[0077] In some implementation schemes, R 5a Independently selected from N(R) 5b 2. Piperidinyl or morpholinyl.
[0078] In some implementation schemes, R 5b It is independently selected from C1-C6 alkyl groups.
[0079] In some implementation schemes, R 5b It is selected independently from CH3.
[0080] In some implementation schemes, R 7It is selected from C1-C6 alkylene groups, C3-C6 cycloalkylene groups, or 3-6 membered heterocyclic groups.
[0081] In some implementation schemes, R 7 Selected from the following groups: -CH2-, -CH(CH3)-, -C(CH3)2-, , or .
[0082] In some implementation schemes, R 7 Selected from the following groups: -CH2-, -CH(CH3)-, -C(CH3)2-, or .
[0083] In some implementation schemes, R 1 Selected from the following groups:
[0084] , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .
[0085] In some implementation schemes, R 1 Selected from the following groups:
[0086] , , , , , , , , , , , , , , , , , or .
[0087] In some implementation schemes, R 2 Selected from H, NH2, CH3, OH or halogens.
[0088] In some implementation schemes, R 2 Selected from H, NH2, CH3 or halogens.
[0089] In some implementation schemes, R 2 Selected from H, NH2 or halogens.
[0090] In some implementation schemes, R 2 Selected from H or NH2.
[0091] In some implementation schemes, R 3 It is independently selected from halogens, C1-C6 alkyl groups, C1-C6 alkoxy groups, or C1-C6 haloalkyl groups.
[0092] In some implementation schemes, R 3 It is independently selected from halogens or C1-C6 alkoxy groups.
[0093] In some implementation schemes, R 3 Selected from F and -OCH3.
[0094] In some implementation schemes, R 3 Selected from halogens.
[0095] In some implementation schemes, R 3 Selected from F.
[0096] In some implementations, m is selected from 0 or 1.
[0097] In some implementation schemes, R 4 Independently selected from halogens, CN, NH2, OH, NO2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, and 3-10 heterocyclic groups, wherein the C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, and 3-10 heterocyclic groups are optionally surrounded by one or more R groups. 4a replace.
[0098] In some implementation schemes, R 4 It is independently selected from CN, halogen, C1-C6 alkyl or C1-C6 alkoxy.
[0099] In some implementation schemes, R 4 It is independently selected from halogens, C1-C6 alkyl groups, or C1-C6 alkoxy groups.
[0100] In some implementation schemes, R 4 It is independently selected from CN or C1-C6 alkyl groups.
[0101] In some implementation schemes, R 4 Selected independently from CN or CH3.
[0102] In some implementation schemes, R 4 It is independently selected from C1-C6 alkyl groups.
[0103] In some implementation schemes, R 4 It is selected independently from CH3.
[0104] In some implementations, n is selected from 0 or 1.
[0105] In some implementation schemes, R 9 Selected from H, NH2, -NHR 10 -NH-C1-C6 alkyl or C1-C6 alkyl, wherein the C1-C6 alkyl or -NH-C1-C6 alkyl is optionally substituted with one or more R 10 replace.
[0106] In some implementation schemes, R 9 Selected from H, CN, OH, NH2, -NHR 10 or -NH-C1-C6 alkyl, wherein the -NH-C1-C6 alkyl is optionally surrounded by one or more R 10 replace.
[0107] In some implementation schemes, R 10 Independently selected from halogens, NH2, C3-C8 cycloalkyl groups, or 3-10 membered heterocyclic groups, wherein the NH2, C3-C8 cycloalkyl groups, or 3-10 membered heterocyclic groups are optionally converted by one or more R groups. 11 replace.
[0108] In some implementation schemes, R 10 Independently selected from halogens, NH2, C3-C6 cycloalkyl groups, 5-6 membered heterocyclic groups, C6-C 10 aryl or 5-6 membered heteroaryl, wherein the NH2, C3-C6 cycloalkyl, 5-6 membered heterocyclic, C6-C 10 aryl or 5-6 heteroaryl groups are optionally surrounded by one or more R groups. 11 replace.
[0109] In some implementation schemes, R 10 Independently selected from NH2, C3-C6 cycloalkyl, 5-6 membered heterocyclic groups, C6-C10 aryl or 5-6 membered heteroaryl, wherein the NH2, C3-C6 cycloalkyl, 5-6 membered heterocyclic, C6-C 10 aryl or 5-6 heteroaryl groups are optionally surrounded by one or more R groups. 11 replace.
[0110] In some implementation schemes, R 10 Independently selected from NH2, 3-10 membered heterocyclic groups, C6-C 10 Aryl or 5-10 membered heteroaryl, wherein the NH2, 3-10 membered heterocyclic group, C6-C 10 aryl or 5-10 heteroaryl groups are optionally surrounded by one or more R groups. 11 replace.
[0111] In some implementation schemes, R 10 Independently selected by one or more R 11 The following groups may be substituted: pyrazolyl, NH2, phenyl, pyridyl, pyrroleyl, tetrahydropyrroleyl or morpholinyl.
[0112] In some implementation schemes, R 11 Independently selected from C1-C6 alkyl, halogen, C1-C3 alkoxy, C3-C6 cycloalkyl or 5-6 membered heterocyclic group, wherein the C1-C6 alkyl, C3-C6 cycloalkyl or 5-6 membered heterocyclic group is optionally substituted with C1-C6 alkyl, halogen, OH, -NH-C1-C6 alkyl or -N(C1-C6 alkyl)2.
[0113] In some implementation schemes, R 11 The group is independently selected from the following groups that are optionally substituted with C1-C6 alkyl, halogen, OH, -NH-C1-C6 alkyl, or -N(C1-C6 alkyl)2: methyl, ethyl, tetrahydropyrrolyl, piperidinyl, -OCH3, F, piperazine, cyclopropyl, or isopropyl.
[0114] In some implementation schemes, R 11 The group is independently selected from the following groups that are optionally substituted with methyl, ethyl, OH, -N(CH3)2 or F: methyl, ethyl, tetrahydropyrrolyl, piperidinyl, -OCH3, F, piperazine, cyclopropyl or isopropyl.
[0115] In some implementation schemes, R 11 It is independently selected from C1-C6 alkyl groups.
[0116] In some implementation schemes, R 9 Selected from the following groups: H, CN, OH, NH2, , , , , , , , , , , , , , , , , , , , , , , or .
[0117] In some embodiments, the compound represented by formula (I), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, is selected from the compound represented by formula (II), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
[0118]
[0119] (II)
[0120] Among them, rings A, X, Y, Z, E, and R 1 R 2 R 3 R 4 n and m are defined as above.
[0121] In some embodiments, the compound represented by formula (I), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, is selected from the compound represented by formula (III), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
[0122]
[0123] (III)
[0124] Among them, rings B, X, Y, Z, E, and R 1 R 2 R 3 R 4 n and m are defined as above.
[0125] In some embodiments, the compound represented by formula (I), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, is selected from the compound represented by formula (IV), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
[0126]
[0127] (IV)
[0128] Among them, X, Y, Z, E, R 1 R 2 R 3 R 4 n and m are defined as above.
[0129] In some embodiments, the compound represented by formula (I), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, is selected from the compound represented by formula (V), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
[0130]
[0131] (V)
[0132] Among them, rings A, B, Y, W, E, and R 1 R 2 R 3 R 4 n and m are defined as above.
[0133] In some embodiments, the compound represented by formula (I), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, is selected from the following compounds, or stereoisomers thereof or pharmaceutically acceptable salts thereof:
[0134]
[0135] or .
[0136] Furthermore, the present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0137] Furthermore, the present invention relates to the use of a compound of formula (I), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for the prevention or treatment of diseases associated with FGFR.
[0138] Furthermore, the present invention relates to the use of a compound of formula (I), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the prevention or treatment of diseases related to FGFR.
[0139] Furthermore, the present invention relates to a compound of formula (I) for the prevention or treatment of diseases associated with FGFR, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0140] The present invention also relates to a method for preventing or treating diseases associated with FGFR, the method comprising administering a therapeutically effective dose of a compound of formula (I) of the present invention, or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, or a pharmaceutical preparation comprising a compound of formula (I) of the present invention, or a stereoisomer or pharmaceutically acceptable salt thereof.
[0141] Furthermore, the diseases associated with FGFR are selected from cancer.
[0142] In some embodiments of this application, the cancer is, for example, a solid tumor, such as gastric cancer.
[0143] On the other hand, the present invention provides the use of a compound of formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for the prevention or treatment of cancer.
[0144] On the other hand, the present invention provides the use of a compound of formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the prevention or treatment of cancer.
[0145] On the other hand, the present invention provides a compound of formula (I) for the prevention or treatment of cancer, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0146] On the other hand, the present invention provides a method for treating cancerous diseases in mammals, comprising administering to a mammal, preferably a human, a therapeutically effective amount of a compound of formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0147] Terminology Definitions and Explanations
[0148] Unless otherwise stated, the definitions of functional groups and terms recorded in this specification and description, including definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, and definitions of specific compounds in the examples, can be arbitrarily combined and combined with each other. Such combinations and combinations of functional group definitions and compound structures should fall within the scope of this specification.
[0149] In this article, " " " indicates a connection point.
[0150] In this article, the double arrows in the synthesis route " "or multiple arrows" "or" "Indicates a multi-step reaction."
[0151] The term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable, non-toxic salt of an acid or base, including salts of inorganic acids and bases, and salts of organic acids and bases.
[0152] The compounds of this invention may have asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers, and single isomers are all included within the scope of this invention.
[0153] The illustrations of racemic or enantiomerically pure compounds in this article are derived from Maehr, J. Chem. Ed. 1985, 62:114-120. Unless otherwise specified, wedge-shaped and dashed lines denote the absolute configuration of a stereocenter. When the compounds described herein contain alkene double bonds or other geometrically asymmetric centers, they include E and Z geometric isomers unless otherwise specified. Similarly, all tautomers are included within the scope of this invention.
[0154] The compounds of this invention can exist in specific geometric or stereoisomeric forms. This invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)- enantiomers, (R)- and (S)- enantiomers, diastereomers, (D)- isomers, (L)- isomers, and racemic mixtures thereof, as well as other mixtures, such as mixtures enriched with enantiomers or diastereomers, all of which are within the scope of this invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are included within the scope of this invention.
[0155] The term "stereoisomer" refers to isomers that are produced by different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, non-corresponding isomers, and conformational isomers.
[0156] The term "tautomer" refers to a functional group isomer resulting from the rapid movement of an atom between two positions within a molecule. The compounds of this invention can exhibit tautomerism. Tautomers can exist in two or more interconvertible forms. Proton-transfer tautomers arise from the migration of covalently bonded hydrogen atoms between two atoms. Tautomers generally exist in equilibrium form; attempts to isolate a single tautomer typically yield a mixture whose physicochemical properties are consistent with those of the mixture of compounds. The equilibrium position depends on the intramolecular chemical characteristics. For example, in many aliphatic aldehydes and ketones, such as acetaldehyde, the ketone form is dominant; while in phenols, the enol form is dominant. This invention encompasses all tautomeric forms of the compounds.
[0157] The term "pharmaceutical composition" refers to a mixture of one or more compounds described herein, or physiologically / pharmaceutical acceptable salts or prodrugs thereof, with other chemical components, such as physiologically / pharmaceutical acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate the administration of the compound to a living organism.
[0158] The term "substitution" refers to the substitution of one or more hydrogen atoms on a specific atom by a substituent, provided that the valence state of the specific atom is normal and the resulting compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are substituted; oxo substitution does not occur on aromatic groups.
[0159] The terms “optional” or “optionally” mean that the event or condition subsequently described may or may not occur, including both the occurrence and non-occurrence of said event or condition. For example, the ethyl group “optionally” being halogenated means that the ethyl group can be unsubstituted (CH2CH3), monosubstituted (e.g., CH2CH2F), polysubstituted (e.g., CHFCH2F, CH2CHF2, etc.), or fully substituted (CF2CF3). Those skilled in the art will understand that for any group containing one or more substituents, no substitution or substitution pattern that is spatially impossible and / or cannot be synthesized is introduced.
[0160] The term "C1-C6 alkyl" should be understood to refer to a straight-chain or branched saturated monovalent hydrocarbon group having 1, 2, 3, 4, 5, or 6 carbon atoms. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl, or 1,2-dimethylbutyl, etc. The term “C1-C3 alkyl” should be understood to refer to a straight-chain or branched saturated monovalent hydrocarbon group having 1, 2, or 3 carbon atoms.
[0161] The term "alkoxy" refers to a group formed by the loss of a hydrogen atom from a hydroxyl group in straight-chain or branched alcohols, and can be understood as "alkyloxy" or "alkyl-O-", where alkyl is as defined above. The term "C1-C6 alkoxy" can be understood as "C1-C6 alkyloxy" or "C1-C6 alkyl-O-". The term "C1-C6 alkoxy" can include a range such as "C1-C3 alkoxy".
[0162] The term "halogen" refers to fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine.
[0163] The term “halogenated alkyl” is intended to include both monohalogenated and polyhalogenated alkyl groups. For example, the term “C1-C6 haloalkyl” means a C1-C6 alkyl group as defined above that is substituted with one or more halogens, including but not limited to trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl, etc.
[0164] The term "haloalkoxy" is intended to include both monohaloalkoxy and polyhaloalkoxy, wherein a halogen is substituted on the alkyl moiety of the alkoxy group. For example, the term "C1-C6 haloalkoxy" means a C1-C6 alkoxy group as defined above that is substituted with one or more halogens.
[0165] The term "C3-C" 10 "Cyclic hydrocarbon group" should be understood as representing a saturated or partially saturated monocyclic or bicyclic hydrocarbon ring with 3 to 10 carbon atoms. It includes C3-C... 10 cycloalkyl and C3-C 10 Partially saturated cyclic hydrocarbon groups (e.g., cycloalkenyl, cycloalkynyl, etc.), the term "C3-C" 10"Cycloalkyl" indicates a saturated monocyclic or bicyclic hydrocarbon ring having 3 to 10 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl, or bicyclic hydrocarbons such as decahydronaphthalene ring. (C3-C) 10 Partially saturated cyclic hydrocarbon groups refer to partially saturated monocyclic or bicyclic hydrocarbon rings having 3 to 10 carbon atoms. Examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, or cyclodecenyl. According to the present invention, the bicyclic hydrocarbon ring includes bridged rings, spirocyclic rings, or fused ring structures. The term "C3-C8 cyclic hydrocarbon group" should be understood to refer to a saturated or partially saturated monocyclic or bicyclic hydrocarbon ring having 3 to 8 atoms, including C3-C8 cycloalkyl and C3-C8 partially saturated cyclic hydrocarbon groups. The term "C3-C8 cycloalkyl" refers to a saturated monocyclic or bicyclic hydrocarbon ring having 3 to 8 carbon atoms. The term “C3-C6 cycloalkyl” should be understood to refer to a saturated or partially saturated monocyclic or bicyclic hydrocarbon ring having 3 to 6 atoms, including C3-C6 cycloalkyl and C3-C6 partially saturated cycloalkyl groups. The term “C3-C6 cycloalkyl” refers to a saturated monocyclic or bicyclic hydrocarbon ring having 3 to 6 carbon atoms.
[0166] Term "C" 6- C 10 "Aryl" should be understood as a monovalent aromatic or partially aromatic monocyclic, bicyclic, or tricyclic hydrocarbon ring having 6, 7, 8, 9, or 10 carbon atoms, particularly a ring with 6 carbon atoms ("C6 aryl"), such as phenyl; or a ring with 9 carbon atoms ("C9 aryl"), such as indenyl or indenyl; or a ring with 10 carbon atoms ("C9 aryl"). 10 Aryl), such as tetrahydronaphthyl, dihydronaphthyl or naphthyl.
[0167] The term "3-12 membered heterocyclic group" should be understood as a saturated or partially unsaturated monocyclic or bicyclic ring having 3-12 ring atoms. The bicyclic ring includes bridged rings, spirocyclic rings, and fused rings. The "hetero" in the heterocyclic group includes, but is not limited to, atoms and / or groups independently selected from N, O, S, C(=O), C(=S), S(=O), and S(O)2, and the number of heteroatoms can be, for example, 1-6 (e.g., 1, 2, 3, 4, 5, or 6). Specifically, the heterocyclic group can be monocyclic, including but not limited to: 4-membered rings, such as azirmonobutyryl and oxobutyryl; 5-membered rings, such as tetrahydrofuranyl, dioxacyclopentenyl, pyrrolyl, imidazoyl, pyrazolyl, pyrrolinyl; or 6-membered rings, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, piperazinyl, 2-piperazinoneyl, or trithiaalkyl; or 7-membered rings, such as diazacycloheptyl. Optionally, the heterocyclic group can be bicyclic, for example, but not limited to, 5,5-membered rings, such as hexahydrocyclopenta[c]pyrrolo-2(1H)-yl rings, or 5,6-membered bicyclic rings, such as hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl rings. The ring may be partially unsaturated, meaning it may contain one or more double bonds, such as, but not limited to, 2,5-dihydro-1H-pyrrole, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl, or 4H-[1,4]thiazinyl; or it may be benzofused, such as, but not limited to, dihydroisoquinolinyl. The term "3-8 membered heterocyclic group" should be understood as a saturated or partially unsaturated monocyclic or bicyclic ring having 3-8 ring atoms. The term "3-6 membered heterocyclic group" should be understood as a saturated or partially unsaturated monocyclic or bicyclic ring having 3-6 ring atoms.
[0168] The term "5-12-membered heteroaryl" should be understood to include monovalent monocyclic, bicyclic, or tricyclic aromatic ring systems, particularly with 5, 6, 9, or 10 ring atoms, and in each case, may be benzofused. The term "heteroaryl" means that the aromatic ring contains, but is not limited to, atoms and / or groups independently selected from N, O, S, C(=O), C(=S), S(=O), and S(O)2, and the number of heteroatoms may be, for example, 1-6 (e.g., 1, 2, 3, 4, 5, or 6). Specifically, the heteroaryl group is selected from thienyl, furanyl, pyrroleyl, oxazolyl, thiazolyl, imidazoleyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, etc., and their benzo[derivatives], such as benzofuranyl, benzothienyl, benzothiazolyl, benzooxazolyl, benzoisooxazolyl, benzoimidazolyl, benzotriazolyl, indazoleyl, indolyl, isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and their benzo[derivatives], such as quinolinyl, quinazolinyl, isoquinolinyl, etc.; or acryloxynyl, inazinyl, purinyl, etc., and their benzo[derivatives]; or terpineyl, phthalazinyl, quinazolinyl, quinoxolinyl, naphthinyl, pteridinyl, carbazolyl, acryloxynyl, phenazinyl, phenothiazinyl, phenothiazinyl, or phenoxazinyl. wait.
[0169] The term "treatment" means administering the compound or preparation described in this application to improve or eliminate a disease or one or more symptoms related to said disease, and includes:
[0170] (i) Suppress the disease or disease state, that is, curb its development;
[0171] (ii) To alleviate a disease or disease state, even if the disease or disease state subsides.
[0172] The term "therapeutic effective amount" means (i) the amount of the compound of the present invention used to treat or prevent a particular disease, condition, or disorder; (ii) to reduce, improve, or eliminate one or more symptoms of a particular disease, condition, or disorder; or (iii) to prevent or delay the onset of one or more symptoms of a particular disease, condition, or disorder described herein. The amount of the compound of the present invention constituting a "therapeutic effective amount" varies depending on the compound, the disease state and its severity, the route of administration, and the age of the mammal to be treated, but may routinely be determined by those skilled in the art based on their own knowledge and the disclosure of this invention.
[0173] The term "individual" includes both mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates (e.g., chimpanzees and other apes and monkeys); livestock such as cattle, horses, sheep, goats, and pigs; domesticated animals such as rabbits, dogs, and cats; and laboratory animals, including rodents such as rats, mice, and guinea pigs. Examples of non-human mammals include, but are not limited to, birds and fish. In one embodiment of the methods and compositions provided herein, the mammal may be a human.
[0174] The term "excipient" refers to a pharmaceutically acceptable inert ingredient. Examples of the term "excipient" include, without limitation, binders, disintegrants, lubricants, flow aids, stabilizers, fillers, and diluents. Excipients enhance the handling properties of pharmaceutical formulations, i.e., by increasing flowability and / or adhesion, making the formulation more suitable for direct compression. Typical examples of "pharmaceutically acceptable carriers" suitable for the above formulations include sugars, starches, cellulose, and their derivatives, which are commonly used excipients in pharmaceutical formulations.
[0175] The term "pharmaceuticalally acceptable excipient" refers to excipients that do not cause significant irritation to the organism and do not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.
[0176] The words “comprise,” “comprise,” or “comprise,” and their English variations such as comprises or comprising, should be understood in an open, non-exclusive sense, meaning “including but not limited to.”
[0177] The compounds of the present invention can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthetic methods, and equivalent substitutions known to those skilled in the art. Preferred embodiments include, but are not limited to, the embodiments of the present invention.
[0178] The chemical reactions in the specific embodiments of this invention are carried out in a suitable solvent, which must be suitable for the chemical changes of this invention and the reagents and materials required therefor. To obtain the compounds of this invention, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction flow based on existing embodiments. Detailed Implementation
[0179] The following embodiments describe the technical solutions of the invention in detail, but the scope of protection of the invention includes, but is not limited to, these embodiments.
[0180] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts are measured in units of 10⁻⁶. -6 (ppm). The solvents used for NMR determination were deuterated dimethyl sulfoxide, deuterated chloroform, deuterated methanol, etc., and the internal standard was tetramethylsilane (TMS).
[0181] Abbreviations:
[0182] DMAP: 4-Dimethylaminopyridine; Et3N or TEA: Triethylamine; THF: Tetrahydrofuran; MeCN or ACN: Acetonitrile; 18-crown-6 or 18-crown-6: 1,4,7,10,13,16-Hexaoxane; Pd(dppf)Cl2: [1,1'-Bis(diphenylphosphine)ferrocene]palladium dichloride; dioxane: Dioxane; Pd(PPh4)3: Tetra(triphenylphosphine)palladium; DIEA or DIPEA: N,N-Diisopropylethylamine; DMF: N,N-Dimethylformamide; HATU: 2-(7-Azobenzotriazole)- N,N,N',N'-Tetramethylurea hexafluorophosphate; NMP: N-methylpyrrolidone; BOP-Cl: Bis(2-oxo-3-oxazolidinyl)phosphine chloride; Pyridine: Pyridine; Pd(OAc)2: Palladium acetate; S-phos: 2-dicyclohexylphosphine-2',6'-dimethoxybiphenyl; DCM: Dichloromethane; BINAP: 1,1'-binaphthyl-2,2'-bisdiphenylphosphine; TCHP: Tricyclohexylphosphine; TFA: Trifluoroacetic acid; LiHMDS: Lithium hexamethyldisilamide; TsCl: p-toluenesulfonyl; MeAC: Acetic acid; TBAF: Tetrabutylammonium fluoride; TsOH: p-toluenesulfonic acid; LAH: Lithium aluminum hydride.
[0183] Example 1
[0184] N-(4-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)phenyl)acryloylamide (1)
[0185]
[0186]
[0187] Step 1: N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboropentane-2-yl)phenyl)acryloylamide (1B)
[0188] 4,4,5,5-Tetramethyl-2-(4-aminophenyl)-1,3,2-dioxoboropentan (5.0 g, 23 mmol, 1 eq), 4-dimethylaminopyridine (0.70 g, 5.7 mmol, 0.25 eq), and triethylamine (4.6 g, 46 mmol, 6.3 mL, 2 eq) were dissolved in tetrahydrofuran (50 mL). Acryloyl chloride (2.5 g, 27 mmol, 2.2 mL, 1.2 eq) in tetrahydrofuran (5 mL) was slowly added dropwise at 0°C. The resulting mixture was stirred at 20°C for 5 hours. The solvent was removed by vacuum distillation, and water (100 mL) was added to the residue. The resulting mixture was extracted with ethyl acetate (100 mL × 3 times). The organic phases were mixed, washed with saturated brine (100 mL × 3 times), dried over anhydrous sodium sulfate, filtered, and the solvent was removed by vacuum distillation. The residue was purified by silica gel column chromatography (eluting phase was a mixture of petroleum ether and ethyl acetate containing 16–18%) to give a white solid, title compound 1B (2.3 g, 8.3 mmol, yield: 36%).
[0189] 1 H NMR (400 MHz, DMSO-d6): δ = 10.24 (s, 1H), 7.73 - 7.66 (m, 2H), 7.65 - 7.59 (m, 2H), 6.50 - 6.39 (m, 1H), 6.31 - 6.22 (m, 1H), 5.77 (d, J =10.8 Hz, 1H), 1.28 (s, 12H).
[0190] Step 2: 2-(4-bromo-2-fluorophenoxy)-4-methylpyrimidine (1E)
[0191] 4-Bromo-2-fluorophenol (5.0 g, 26 mmol, 1.0 eq) and 2-chloro-4-methylpyrimidine (3.7 g, 29 mmol, 1.1 eq) were dissolved in acetonitrile (30 mL), and potassium carbonate (7.2 g, 52 mmol, 2.0 eq) and 18-crown-6 (0.69 g, 2.6 mmol, 0.10 eq) were added. The resulting mixture was stirred at 85°C for 12 hours, cooled, and extracted with water (100 mL) and ethyl acetate (100 mL × 3 times). The resulting organic phases were mixed, washed with saturated brine (100 mL × 3 times), dried over anhydrous sodium sulfate, filtered, and the solvent was removed by vacuum distillation. The residue was purified by silica gel column chromatography (elution phase was a mixture of petroleum ether and ethyl acetate containing 0-15% ethyl acetate) to give a white solid, title compound 1E (7.2 g, yield: 97%).
[0192] 1 H NMR (400 MHz, CDCl3): δ = 8.35 (d, J = 5.2 Hz, 1H), 7.42 - 7.28(m, 2H), 7.22 - 7.10 (m, 1H), 6.95 (d, J = 5.2 Hz, 1H), 2.50 (s, 3H).
[0193] Step 3: 2-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxoboropentane-2-yl)phenoxy)-4-methylpyrimidine (1G)
[0194] Compound 1E (4.7 g, 17 mmol, 1.0 eq), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxoboronylcyclopentane) (5.1 g, 20 mmol, 1.2 eq), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (1.2 g, 1.7 mmol, 0.1 eq), and potassium acetate (4.9 g, 50 mmol, 3 eq) were mixed in dioxane (100 mL). The mixture was stirred at 80°C under a nitrogen atmosphere for 3 hours. Acetonitrile (100 mL) was added to the mixture, and the mixture was stirred for 30 minutes and then filtered. The filtrate was concentrated to give a black solid, which was the title compound 1G (10 g, crude).
[0195] MS (ESI+) m / z = 331.0[M+H].
[0196] Step 4: 6-Chloro-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-amine (1I)
[0197] 6-Chloro-5-iodo-4-aminopyrimidine (1.7 g, 6.7 mmol, 1.0 eq), compound 1G (2.2 g, 6.7 mmol, 1.0 eq), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (0.49 g, 0.67 mmol, 0.10 eq), and potassium phosphate (2.8 g, 13 mmol, 2.0 eq) were mixed in dioxane (40 mL) and water (4 mL). The resulting mixture was stirred at 85°C under a nitrogen atmosphere for 2 hours. The solvent was removed by vacuum distillation of the yellow reaction solution, and the residue was purified by silica gel column chromatography (eluting phase was a mixture of petroleum ether and ethyl acetate containing 33–100% ethyl acetate) to give a pale yellow solid, title compound 1I (1.10 g, yield: 50%).
[0198] 1H NMR (400 MHz, DMSO-d6): δ = 8.49 (d, J = 5.2 Hz, 1H), 8.23 (s,1H), 7.48 (t, J = 8.4 Hz, 1H), 7.37 (d, J = 11.2 Hz, 1H), 7.21 (d, J = 5.2Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 2.45 (s, 3H).
[0199] Step 5: N-(4-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)phenyl)acryloylamide (1)
[0200] Compound 1I (0.24 g, 0.72 mmol, 1.0 eq), compound 1B (0.19 g, 0.72 mmol, 1.0 eq), tetraphenylphosphine palladium (84 mg, 0.073 mmol, 0.10 eq), and potassium carbonate (0.20 g, 1.5 mmol, 2.0 eq) were mixed in dioxane (10 mL) and water (1 mL). The resulting mixture was stirred at 85°C under a nitrogen atmosphere for 18 hours. A saturated ammonium chloride solution (20 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (30 mL × 3 times). The resulting organic phases were mixed, washed with saturated brine (100 mL × 3 times), dried over anhydrous sodium sulfate, filtered, and the solvent was removed by vacuum distillation. The residue was purified by preparative chromatography and lyophilized to give a white solid, title compound 1 (0.15 g, yield: 46%).
[0201] MS (ESI+) m / z = 443.1[M+H].
[0202] 1 H NMR(400 MHz, DMSO-d6): δ = 10.20 (s, 1H), 8.50 (d, J = 5.2 Hz,1H), 8.46 (s, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.34 (t, J = 8.4 Hz, 1H), 7.29 -7.14 (m, 4H), 7.00 (dd, J1 = 8.4 Hz, J2 = 1.2 Hz, 1H), 6.74 - 6.29 (m, 3H), 6.29 - 6.19 (m, 1H), 5.76 (dd, J1 = 10.0 Hz, J2 = 2.0 Hz, 1H), 2.43 (s, 3H).
[0203] Example 2
[0204] N-(4-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)phenyl)methacryloylamide (2)
[0205]
[0206] Step 1: N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboropentane-2-yl)phenyl)methacryloylamide (2B)
[0207] 4,4,5,5-Tetramethyl-2-(4-aminophenyl)-1,3,2-dioxoboropentan (0.20 g, 0.91 mmol, 1 eq), methacrylic acid (0.16 g, 1.8 mmol, 2.0 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (0.69 g, 1.8 mmol, 2 eq), and N,N-diisopropylethylamine (0.24 g, 0.18 mmol, 2.0 eq) were dissolved in acetonitrile (50 mL). The resulting mixture was stirred at 25°C under a nitrogen atmosphere for 2 hours. The solvent was removed by vacuum distillation, and water (30 mL) was added to the residue. The resulting mixture was extracted with ethyl acetate (30 mL × 3 times). The organic phases were mixed, washed with saturated brine, dried with anhydrous sodium sulfate, filtered, and the solvent was removed by vacuum distillation. The residue was purified by silica gel column chromatography (eluting phase was a mixture of petroleum ether and ethyl acetate containing 0–50% ethyl acetate) to give the title compound 2B (0.20 g, yield: 76%) as a pale yellow solid.
[0208] 1 H NMR (400 MHz, CDCl3): δ = 7.79 (d, J = 8.4 Hz, 2H), 7.59 (d, J =8.4 Hz, 2H), 5.80 (s, 1H), 5.48 (d, J = 1.2 Hz, 1H), 2.07 (s, 3H), 1.35 (s,12H)
[0209] Step 2: N-(4-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)phenyl)methacryloylamide (2)
[0210] Compound 1I (0.030 g, 0.090 mmol, 1.0 eq), compound 2B (0.029 g, 0.099 mmol, 1.0 eq), tetraphenylphosphine palladium (0.010 mg, 9.4 µmol, 0.10 eq), and potassium carbonate (0.025 g, 0.18 mmol, 2.0 eq) were mixed in dioxane (5 mL) and water (0.5 mL). The resulting mixture was stirred at 80°C under a nitrogen atmosphere for 2 hours. A saturated ammonium chloride solution (20 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (30 mL × 3 times). The resulting organic phases were mixed, washed with saturated brine (20 mL × 3 times), dried over anhydrous sodium sulfate, filtered, and the solvent was removed by vacuum distillation. The residue was preparatively purified by chromatography and lyophilized to give a white solid, title compound 2 (3.9 mg, yield: 9.2%).
[0211] MS (ESI+) m / z = 457.2[M+1].
[0212] 1 H NMR (400 MHz, MeOD-d4): δ = 9.50 - 9.40 (m, 2H), 8.61 - 8.56 (m,2H), 8.37 - 8.30 (m, 3H), 8.19 - 8.14 (m, 2H), 8.12 - 8.08 (m, 1H), 6.79 (s,1H), 6.52 (s, 1H), 3.51 (s, 3H), 3.02 (s, 3H)
[0213] Example 3
[0214] 6-(6-ethynyl-4-methylpyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-amine (3)
[0215]
[0216] Step 1: 5-Bromo-4-methyl-2-((triisopropylsilyl)ethynyl)pyridine (3C)
[0217] Compound 3A (10 g, 40 mmol, 1.0 eq), compound 3B (7.3 g, 40 mmol, 9.0 mL, 1.0 eq), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (2.9 g, 4.0 mmol, 0.10 eq), cuprous iodide (0.76 g, 4.0 mmol, 0.10 eq), and triethylamine (8.1 g, 80 mmol, 11 mL, 2.0 eq) were mixed in N,N-dimethylformamide (50 mL). The resulting mixture was stirred at 85°C under a nitrogen atmosphere for 2 hours. A saturated ammonium chloride solution (100 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (100 mL × 3 times). The resulting organic phases were mixed, washed with saturated brine (50 mL × 3 times), dried over anhydrous sodium sulfate, filtered, and the solvent was removed by vacuum distillation. The residue was purified by silica gel column chromatography (eluting phase was a mixture of petroleum ether and ethyl acetate containing 5–12% ethyl acetate) to give a white solid, title compound 3C (8.5 g, yield: 61%).
[0218] 1 H NMR (400 MHz, CDCl3): δ = 8.56 - 8.47 (m, 1H), 7.26 (s, 1H), 2.30 (s, 3H), 1.08 - 1.06 (m, 21H)
[0219] Step 2: 4-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxoboropentane-2-yl)-2-((triisopropylsilyl)ethynyl)pyridine (3D)
[0220] Compound 3C (4.0 g, 11 mmol, 1.0 eq), compound 1F (5.8 g, 23 mmol, 2.0 eq), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (0.83 g, 1.1 mmol, 0.10 eq), and potassium acetate (2.2 g, 23 mmol, 2.0 eq) were mixed in 1,4-dioxane (40 mL). The resulting mixture was stirred at 80°C under a nitrogen atmosphere for 3 hours. The solvent was removed by vacuum distillation, and the residue was purified by C18 reversed-phase silica gel column chromatography (eluting phase: aqueous solution containing 20–100% acetonitrile) and lyophilized to give a white solid, title compound 3D (0.80 g, yield: 16%).
[0221] 1H NMR (400 MHz, DMSO-d6): δ = 8.61 (s, 1H), 7.38 (s, 1H), 2.45 (s,3H), 1.31 (s, 12H), 1.18 - 1.04 (m, 21H)
[0222] Step 3: 5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-6-(4-methyl-6-((triisopropylsilyl)ethynyl)pyridin-3-yl)pyrimidin-4-amine (3E)
[0223] Compound 1I (0.060 g, 0.18 mmol, 1.0 eq), compound 3D (0.073 g, 0.18 mmol, 1.0 eq), tetraphenylphosphine palladium (0.021 mg, 18 µmol, 0.10 eq), and potassium carbonate (0.075 g, 0.54 mmol, 3.0 eq) were mixed in dioxane (3 mL) and water (0.3 mL). The resulting mixture was stirred at 85°C under a nitrogen atmosphere for 12 hours. The solvent was removed by vacuum distillation, and the residue was purified by preparative chromatography and lyophilized to give a white solid, title compound 3E (75 mg, yield: 73%).
[0224] 1 H NMR (400 MHz, CDCl3): δ = 8.59 (s, 1H), 8.26 (d, J = 5.2 Hz, 1H), 8.13 (s, 1H), 7.19 - 7.14 (m, 2H), 6.92 - 6.82 (m, 3H), 5.29 - 5.07 (m, 2H),2.40 (s, 3H), 2.13 (s, 3H), 1.10 - 1.03 (m, 21H)
[0225] Step 4: 6-(6-ethynyl-4-methylpyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-amine (3)
[0226] Compound 3E (70 mg, 0.12 mmol, 1.0 eq) was dissolved in 2 mL of tetrahydrofuran, and triethylamine trifluoroate (0.20 g, 1.2 mmol, 0.20 mL, 10 eq) was added. The resulting mixture was stirred at 40 °C under a nitrogen atmosphere for 3 hours. The solvent was removed by vacuum distillation, and the residue was purified by preparative chromatography and lyophilized to give a white solid, title compound 3 (24 mg, yield: 47%).
[0227] MS (ESI+) m / z = 413.1[M+H].
[0228] 1 H NMR (400 MHz, DMSO-d6): δ = 8.45 (d, J = 5.2 Hz, 1H), 8.48 (s, 1H), 8.16 (s, 1H), 7.40 (s, 1H), 7.28 - 7.21 (m, 2H), 7.16 (d, J = 5.2 Hz, 1H),7.04 - 6.45 (m, 3H), 4.29 (s, 1H), 2.38 (s, 3H), 2.14 (s, 3H)
[0229] Example 4
[0230] N-(1-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)piperidin-4-yl)acryloylamide (4)
[0231]
[0232] Step 1: 1-tert-butyloxycarbonyl-4-acryloylaminopiperidine (4C)
[0233] 1-tert-butyloxycarbonyl-4-aminopiperidine (3.0 g, 15 mmol, 1.0 eq) and N,N-diisopropylethylamine (3.9 g, 30 mmol, 6.3 mL, 2.0 eq) were dissolved in dichloromethane (40 mL). Acryloyl chloride (2.0 g, 22 mmol, 1.8 mL, 1.5 eq) in dichloromethane (5 mL) was slowly added dropwise at 0°C. The resulting mixture was stirred at 20°C for 3 hours. The solvent was removed by vacuum distillation, and the residue was purified by silica gel column chromatography (eluting phase was a mixture of petroleum ether and ethyl acetate containing 0–50% ethyl acetate) to give the title compound 4C (2.5 g, yield: 66%) as a white solid.
[0234] 1H NMR (400 MHz, CDCl3): δ = 6.29 (dd, J = 1.3, 16.0Hz, 1H), 6.12 -6.03 (m, 1H), 5.65 (dd, J = 1.3, 10.4 Hz, 1H), 5.57 (br d, J = 8.0 Hz, 1H), 4.15 - 3.91 (m, 3H), 2.87 (t, J = 12.0 Hz, 2H), 2.00 - 1.87 (m, 2H), 1.46 (s, 9H), 1.39 - 1.30 (m, 2H).
[0235] Step 2: 4-Acryloylamidopiperidine hydrochloride (4D)
[0236] Compound 4C (2.0 g, 7.9 mmol, 1.0 eq) was dissolved in dichloromethane (15 mL), and 4M dioxane hydrochloride solution (7.86 mL, 4.0 eq) was slowly added dropwise at 0°C. The resulting mixture was stirred at 20°C for 2 hours. The solvent was removed by vacuum distillation to give solid title compound 4D (2.5 g, crude product).
[0237] 1 H NMR (400 MHz, DMSO-d6): δ = 8.30 (d, J = 7.2 Hz, 1H), 6.28 - 6.19(m, 1H), 6.14 - 6.06 (m, 1H), 5.60 (dd, J = 2.3, 10.0 Hz, 1H), 3.30 - 3.19(m, 2H), 3.03 - 2.86 (m, 2H), 1.92 (dd, J = 3.0, 13.6 Hz, 2H), 1.72 - 1.56(m, 2H).
[0238] Step 3: N-(1-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)piperidin-4-yl)acryloylamide (4)
[0239] Compound 4D (0.50 g, 3.2 mmol, 1 eq), compound 1I (0.11 mg, 0.32 mmol, 0.1 eq), and N,N-diisopropylethylamine (0.84 g, 6.5 mmol, 1.1 mL, 2.0 eq) were dissolved in N-methylpyrrolidone (3 mL). The resulting mixture was microwave-heated at 120°C under a nitrogen atmosphere with stirring for 1 hour. The resulting reaction solution was purified by preparative chromatography (Waters Xbridge C18, 20-70% acetonitrile aqueous solution (containing 0.01% ammonia)) and lyophilized to give a white solid, title compound 4 (1.6 mg, yield: 1.0%).
[0240] MS (ESI+) m / z = 450.1[M+H].
[0241] 1 H NMR (400 MHz, MEOD-d4): δ = 8.43 (d, J = 5.2 Hz, 1H), 8.25 (s, 1H), 7.53 (t, J = 8.2 Hz, 1H), 7.38 (dd, J = 1.8, 10.8 Hz, 1H), 7.30 (d, J = 7.6Hz, 1H), 7.18 (d, J = 5.2 Hz, 1H), 6.20 (d, J = 6.4 Hz, 2H), 5.64 (t, J = 6.0Hz, 1H), 4.07 (br d, J = 13.6 Hz, 2H), 3.98 - 3.89 (m, 1H), 3.31 (s, 10H), 3.04 (t, J = 11.6 Hz, 2H), 2.48 (s, 3H), 1.83 (d, J = 10.8 Hz, 2H), 1.46 -1.36 (m, 2H)
[0242] Example 5
[0243] 1-(4-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)-2-methylprop-2-en-1-one(5)
[0244]
[0245] Step 1: 4-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (5B)
[0246] Compound 1I (1.1 g, 3.32 mmol, 1.0 eq), compound 5A (1.1 g, 3.5 mmol, 1.1 eq), tetraphenylphosphine palladium (0.24 g, 0.33 mmol, 0.10 eq), and potassium carbonate (1.4 g, 10 mmol, 3.0 eq) were mixed in dioxane (30 mL) and water (3 mL). The resulting mixture was stirred at 85°C under a nitrogen atmosphere for 12 hours. The solvent was removed by vacuum distillation, and the residue was purified by silica gel column chromatography (eluting phase was a mixture of dichloromethane and 0-10% methanol) to give a brown solid, title compound 5B (0.70 g, yield: 44%).
[0247] 1 H NMR (400 MHz, CDCl3): δ = 8.56 (s, 1H), 8.38 (d, J = 5.2 Hz, 1H), 7.37 (t, J = 8.0 Hz, 1H), 7.17 - 7.06 (m, 2H), 6.96 (d, J = 5.2 Hz, 1H), 5.84(s, 1H), 5.31 (s, 1H), 5.00 (s, 2H), 3.90 (s, 2H), 3.49 - 3.33 (m, 2H), 2.51(s, 3H), 1.45 (s, 9H)
[0248] Step 2: 5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-6-(1,2,3,6-tetrahydropyridin-4-yl)pyrimidin-4-amine hydrochloride (5C)
[0249] Compound 5B (0.20 g, 0.42 mmol, 1.0 eq) was dissolved in dichloromethane (5 mL), and 4M dioxane hydrochloride solution (1.04 mL, 10 eq) was slowly added dropwise at 0°C. The resulting mixture was stirred at 25°C for 1 hour. The solvent was removed by vacuum distillation to give solid title compound 5C (0.18 g, crude product).
[0250] MS (ESI+) m / z = 378.9[M+H].
[0251] Step 3: 1-(4-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)-2-methylprop-2-en-1-one (5)
[0252] Compound 5C (0.16 g, 0.39 mmol, 1.0 eq) and triethylamine (0.12 g, 1.2 mmol, 0.16 mL, 3.0 eq) were dissolved in dichloromethane (5 mL), and methacryloyl chloride (42 mg, 0.40 mmol, 1.0 eq) was slowly added dropwise at 0°C. The resulting mixture was stirred at 25°C for 1 hour. The solvent was removed by vacuum distillation, and the residue was preparatively purified (Waters Xbridge C18, 20-70% acetonitrile aqueous solution (containing 0.01% ammonia)) to give a white solid, title compound 5 (0.070 g, yield: 39%).
[0253] MS (ESI+) m / z = 447.2[M+H].
[0254] 1 H NMR (400 MHz, DMSO-d6): δ = 8.46 (d, J = 4.8 Hz, 1H), 8.37 (s, 1H), 7.38 (t, J = 8.2 Hz, 1H), 7.24 (dd, J1 = 11.2 Hz, J2 = 2.0 Hz, 1H), 7.17 (d, J= 5.2 Hz, 1H), 7.10 (td, J = 8.4, 0.8 Hz, 1H), 6.17 (s, 2H), 5.61 (s, 1H),5.20 - 5.03 (m, 1H), 4.90 (s, 1H), 3.89 (q, J = 2.8 Hz, 2H), 3.49 (t, J = 5.6Hz, 2H), 2.43 (s, 3H), 2.22 (d, J = 2.0 Hz, 2H), 1.79 (s, 3H).
[0255] Example 6
[0256] 1-(2-Methacryl)-(4-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)piperidine(6)
[0257]
[0258] Step 1: 4-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)piperidin-1-carboxylic acid tert-butyl ester (6A)
[0259] Compound 5B (0.40 g, 0.84 mmol, 1.0 eq) was dissolved in methanol (20 mL), and 10% palladium on carbon (0.050 g) was added. The resulting mixture was stirred at 30°C for 12 hours under a hydrogen atmosphere. The reaction solution was filtered to remove the palladium on carbon, and the solvent was removed by vacuum distillation. The residue was slurried with a petroleum ether solution containing 10% ethyl acetate and filtered to give solid title compound 6A (0.34 g, yield: 85%).
[0260] 1 H NMR (400 MHz, DMSO-d6): δ = 8.51 (d, J = 5.2 Hz, 1H), 8.40 - 8.31(m, 1H), 7.52 - 7.43 (m, 1H), 7.31 (dd, J = 11.2 Hz, 1.2 Hz, 1H), 7.22 (d, J= 5.2 Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 6.24 (s, 2H), 4.18 - 3.81 (m, 4H), 3.17 (s, 1H), 2.44 (s, 3H), 1.70 - 1.59 (m, 2H), 1.53 (d, J = 12.8 Hz, 2H),1.40 (s, 9H)
[0261] Step 2: 5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-6-(piperidin-4-yl)pyrimidin-4-amine hydrochloride (6B)
[0262] Compound 6A (0.30 g, 0.62 mmol, 1.0 eq) was dissolved in dichloromethane (5 mL), and 4M dioxane hydrochloride solution (1 mL) was slowly added dropwise at 0°C. The resulting mixture was stirred at 25°C for 1 hour. The solvent was removed by vacuum distillation to give solid title compound 6B (0.39 g, crude product).
[0263] MS (ESI+) m / z = 381.2[M+H].
[0264] Step 3: 1-(2-methacryloyl)-(4-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)piperidine (6)
[0265] Compound 6B (0.39 g, 0.94 mmol, 1.0 eq) and triethylamine (0.28 g, 1.2 mmol, 0.16 mL, 3.0 eq) were dissolved in dichloromethane (5 mL), and methacryloyl chloride (98 mg, 0.94 mmol, 1.0 eq) was slowly added dropwise at 0°C. The resulting mixture was stirred at 25°C for 1 hour. The solvent was removed by vacuum distillation, and the residue was purified by preparative chromatography (Waters Xbridge C18, 20-70% acetonitrile aqueous solution (containing 0.01% ammonia)) to give a white solid, title compound 6 (0.075 g, yield: 18%).
[0266] MS (ESI+) m / z = 449.2[M+H].
[0267] 1 H NMR (400 MHz, DMSO-d6): δ = 8.51 (d, J = 5.2 Hz, 1H), 8.37 (s, 1H), 7.49 (t, J = 8.4 Hz, 1H), 7.38 - 7.27 (m, 1H), 7.22 (d, J = 5.2 Hz, 1H), 7.13(d, J = 8.0 Hz, 1H), 6.28 (s, 2H), 5.14 (s, 1H), 4.93 (s, 1H), 4.37 (s, 1H), 3.87 (s, 1H), 2.99 - 2.74 (m, 1H), 2.64 - 2.55 (m, 1H), 2.45 (s, 3H), 1.85 (s, 3H), 1.76 - 1.54 (m, 5H)
[0268] Example 7
[0269] 6-(4-propynamidophenyl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-4-aminopyrimidine (7)
[0270]
[0271] Step 1: 6-(4-aminophenyl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-4-aminopyrimidine (7A)
[0272] Compound 1I (6.0 g, 18.1 mmol), compound 1A (4.0 g, 18.1 mmol), tetraphenylphosphine palladium (2.1 g, 1.81 mmol), and potassium carbonate (5.0 g, 36.2 mmol) were mixed in dioxane (80 mL) and water (8 mL). The resulting mixture was stirred at 100°C under a nitrogen atmosphere for 2 hours. The reaction solution was cooled and the solvent was removed by vacuum distillation. The residue was purified by silica gel column chromatography (eluting phase was a mixture of dichloromethane and 0-10% methanol) to give a brown solid, title compound 7A (6.0 g, yield: 85%).
[0273] MS (ESI+) m / z = 389.2[M+H].
[0274] 1 H NMR (400 MHz, DMSO- d6): δ= 8.56 - 8.46 (m, 1H), 8.38 (s, 1H), 7.69 - 7.49 (m, 1H), 7.35 (t, J = 8.4 Hz, 1H), 7.22 - 7.15 (m, 2H), 7.01 (d,J = 8.4 Hz, 2H), 6.37 (d,J = 8.4 Hz, 2H), 5.33 (s, 2H), 2.44 (s, 3H)
[0275] Step 2: 6-(4-propynamidophenyl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-4-aminopyrimidine (7)
[0276] Compound 7B (54 mg, 0.77 mmol) was dissolved in dichloromethane (5 mL), and bis(2-oxo-3-oxazolyl)phosphine chloride (0.26 g, 1.0 mmol), compound 7A (0.20 g, 0.51 mmol), and N,N-diisopropylethylamine (0.26 g, 2.0 mmol) were slowly added dropwise at 0°C. The resulting mixture was stirred at 0°C for 1 hour. The solvent was removed by vacuum distillation, and the crude product was purified by preparative chromatography (Waters Xbridge C18, 20-70% acetonitrile aqueous solution (containing 0.01% ammonia)) to give title compound 7 (23 mg, yield: 10%).
[0277] MS (ESI+) m / z = 441.1[M+H].
[0278] 1H NMR (400 MHz, DMSO-d6): δ= 10.85 (s, 1H), 8.49 (d, J = 5.2 Hz, 1H), 8.45 (s, 1H), 7.47 (d, J = 8.8 Hz, 2H), 7.33 (t, J = 8.4 Hz, 1H), 7.27 - 7.14(m, 4H), 6.98 (dd, J = 8.4, 1.6 Hz, 1H), 6.52 (s, 2H), 4.43 (s, 1H), 2.42 (s,3H).
[0279] Example 8
[0280] Following a similar synthetic route and steps as in Example 7, in the second step, replacing raw material 7B with raw material A from the table below can synthesize the following compounds 8-14.
[0281]
[0282]
[0283] Example 9
[0284] Following a similar synthetic route and steps as in Example 7, replacing raw material 1A with raw material B from the table below in the first step, and replacing propynic acid 7B with raw material C in the second step, can synthesize the corresponding compounds 15-26 as follows.
[0285]
[0286]
[0287]
[0288]
[0289]
[0290] The synthetic route for compound 23A is as follows:
[0291]
[0292] Compound 23A can be synthesized using a similar synthetic procedure to that of compound 3D in step two of Example 3. MS (ESI+) m / z = 263.2 [M+H].
[0293] Example 10
[0294] Following a similar synthetic route and steps as in Example 5, by replacing 5A with different raw material D in the table below in the first step, and by replacing methacryloyl chloride with acryloyl chloride in the third step, compounds 27-29 corresponding to those in the table below can be synthesized.
[0295]
[0296]
[0297] Example 11
[0298] N-(4-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)phenyl)ethylenesulfonamide (30)
[0299]
[0300] Compound 7A (150 mg, 0.39 mmol) and pyridine (122 mg, 1.54 mmol) were dissolved in dichloromethane (5 mL), and chloroethylsulfonyl chloride 30A (69 mg, 0.42 mmol) was slowly added dropwise at 0°C. The resulting mixture was stirred at 0°C for 3 hours. The solvent was removed by vacuum distillation, and the crude product was purified by preparative chromatography (Phenomenex Luna C). 18 The title compound 30 (13 mg, yield: 7.3%) was obtained by mixing 100*30mm*5um with a 5-35% acetonitrile aqueous solution as the mobile phase.
[0301] MS (ESI+) m / z = 479.2[M+H].
[0302] 1 H NMR (400 MHz, DMSO-d6) δ 10.17 ( s, 1H), 8.49 (d, J = 5.2 Hz, 1H), 8.43 (s, 1H), 7.32 (t, J = 8.4 Hz, 1H), 7.23 - 7.17 (m, 4H), 7.01 - 6.94 (m,3H), 6.74 (dd, J = 16.4, 9.6 Hz, 1H), 6.50 (s, 2H), 6.06 (d, J = 16.4 Hz,1H), 5.97 (d, J = 9.6 Hz, 1H), 2.43 (s, 3H).
[0303] Example 12
[0304] 1-(2-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)-2,7-diazaspiro[3.5]nonane-7-yl)prop-2-en-1-one (31)
[0305]
[0306] Step 1: 2-(6-amino-5-iodopyrimidin-4-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester (31C)
[0307] Compound 31A (0.50 g, 2.2 mmol), compound 31B (1.1 g, 2.3 mmol), and potassium carbonate (0.61 g, 4.4 mmol) were mixed in dioxane (30 mL). The resulting mixture was stirred at 80°C under a nitrogen atmosphere for 4 hours. The solvent was removed by vacuum distillation, and the residue was purified by silica gel column chromatography (eluting phase was a mixture of petroleum ether and ethyl acetate containing 25-50% ethyl acetate) to give a pale yellow solid, title compound 31C (1.04 g, yield: 97%).
[0308] MS (ESI+) m / z = 446.3[M+H].
[0309] Step 2: 2-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester (31D)
[0310] Compound 31C (0.50 g, 0.92 mmol), compound 1G (0.36 g, 1.1 mmol), palladium acetate (10 mg, 46 μmol), 2-dicyclohexylphosphine-2',6'-dimethoxybiphenyl (38 mg, 92 μmol), and potassium carbonate (0.25 g, 1.84 mmol) were mixed in dioxane (7.5 mL) and water (0.75 mL). The resulting mixture was stirred at 85°C under a nitrogen atmosphere for 12 hours. The solvent was removed by vacuum distillation, and the residue was purified by silica gel column chromatography (eluting phase was a mixture of dichloromethane and 0-10% methanol) to give a brown solid, title compound 31D (60 mg, yield: 12%).
[0311] MS (ESI+) m / z = 522.1 [M+H].
[0312] Step 3: 5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-6-(2,7-diazaspiro[3.5]nonane-2-yl)-4-aminopyrimidine (31E)
[0313] Compound 31D (60 mg, 0.11 mmol) was dissolved in dichloromethane (2 mL), and 4 M dioxane hydrochloride solution (1.0 mL) was slowly added dropwise at 0°C. The resulting mixture was stirred at 25°C for 1 hour. The solvent was removed by vacuum distillation to give solid hydrochloride of title compound 31E (80 mg, crude product).
[0314] MS (ESI+) m / z = 422.1[M+H].
[0315] Step 4: 1-(2-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)-2,7-diazaspiro[3.5]nonane-7-yl)prop-2-en-1-one (31)
[0316] Compound 31E (32 mg, 75 μmol) and triethylamine (32 mg, 0.32 mmol) were dissolved in dichloromethane (5 mL), and a dichloromethane solution of acryloyl chloride 4B (5.8 mg, 64 μmol, 64 μL, 1.0 mol / L) was slowly added dropwise at 0°C. The resulting mixture was stirred at 25°C for 1 hour. The solvent was removed by vacuum distillation, and the residue was purified by preparative chromatography (Phenomenex Luna C). 18 150*25mm*10um, with an eluent of 3%-33% acetonitrile-water (containing 0.1% TFA), yielded a white solid, title compound 31 (11 mg, yield: 30%).
[0317] MS (ESI+) m / z = 476.2[M+H].
[0318] 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J = 5.2 Hz, 1H), 7.98 (s, 1H), 7.40 (t, J = 8.4 Hz, 1H), 7.27 (dd, J = 11.2, 1.6 Hz, 1H), 7.18 (d, J = 5.2Hz, 1H), 7.12 (dd, J = 8.4, 1.2 Hz, 1H), 6.76 (dd, J = 16.4, 10.4 Hz, 1H), 6.05 (dd, J =16.4, 2.4 Hz, 1H), 5.79 (br s, 2H), 5.65 - 5.60 (m, 1H), 3.41 -3.34 (m, 8H), 2.37 (s, 3H), 1.55 (br s, 4H).
[0319] Example 13
[0320] Following a similar synthetic route and steps as in Example 12, by replacing 31A with different raw material E in the table below in the first step, compounds 32-43 corresponding to those in the table below can be synthesized.
[0321]
[0322]
[0323]
[0324]
[0325]
[0326] Example 14
[0327] N-(1-(6-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)azacyclobutyl-3-yl)ethylenesulfonamide (44)
[0328]
[0329] Following a similar synthetic route and steps as in Example 12, 31A was replaced with 34A in the first step, and 4B of acryloyl chloride was replaced with 2-chloroethylsulfonyl chloride 30A in the fourth step, to synthesize compound 44.
[0330] MS (ESI+) m / z = 458.1 [M+H].
[0331] 1HNMR (400 MHz, DMSO-d6) δ 8.48 (d, J = 5.2 Hz, 1H), 8.24 - 7.72 (m,2H), 7.41 (t, J = 8.4 Hz, 1H), 7.33 - 7.16 (m, 2H), 7.09 ( d, J = 8.8 Hz,1H), 6.67 (dd, J = 16.8, 9.6 Hz, 1H), 5.99 (d, J = 16.4 Hz, 1H), 5.91 (d, J =9.6 Hz, 1H), 5.85 (s, 2H), 3.89 (d, J = 4.8 Hz, 1H), 3.71 (t, J = 8.0 Hz,2H), 3.56 - 3.45 (m, 2H), 2.41 (s, 3H).
[0332] Example 15
[0333] Using compound 34E as a starting material, the synthesis method of step 2 in Example 7 was adopted, replacing starting material C in the table below with 7B, to synthesize the corresponding compounds 45-48.
[0334]
[0335]
[0336] Example 16
[0337] Using a similar synthesis method and steps as in Example 1, but replacing 1H in step 4 with the starting material F in the table below, the corresponding compounds 49-55 were synthesized.
[0338]
[0339]
[0340] Compound 54 is synthesized from its precursor 54B via the following steps.
[0341]
[0342] 54A (500 mg, 3.3 mmol) was dissolved in 10 mL of dichloromethane, and iodine chloride (1.6 g, 10 mmol) was slowly added dropwise under a nitrogen atmosphere at 0°C. After reacting the resulting solution at room temperature for 1 hour, the reaction was quenched with 5 mL of saturated sodium sulfite solution, followed by extraction with 25 mL of dichloromethane. The organic phase was dried over anhydrous sodium sulfate, and the solvent was removed by vacuum distillation. The crude product was purified by silica gel column chromatography (eluting phase: 0-100% ethyl acetate in petroleum ether) to give compound 54B (410 mg, yield: 45%).
[0343] Example 17
[0344] N-(4-(6-amino-5-(4-((S)-2-cyanopyrrolidine-1-carbonyl)cyclohex-1-en-1-yl)pyrimidin-4-yl)phenyl)-2-butynamide (55)
[0345]
[0346] Step 1: Ethyl 4-(4-amino-6-chloropyrimidin-5-yl)cyclohexyl-3-ene-1-carboxylate (55B)
[0347] 4-Amino-6-chloro-5-iodopyrimidine 1H (2.0 g, 7.8 mmol), compound 55A (2.6 g, 9.4 mmol), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (0.57 g, 0.78 mmol), and potassium carbonate were added. (2.2 g, 16 mmol) was dissolved in dioxane (20 mL) and water (2 mL), and after purging with nitrogen three times, the mixture was stirred at 100 °C for 2 hours. After cooling, 20 mL of saturated ammonium chloride solution was added and extracted with 40 mL of ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (eluting phase: petroleum ether containing 50% ethyl acetate) to give solid compound 55B (1.1 g, yield: 50%).
[0348] 1 H NMR (400 MHz, DMSO-d6) δ 8.09 (s, 1H), 7.56 - 6.28 (m, 2H), 5.67 (s, 1H), 4.16 - 4.03 (m, 2H), 2.99 - 2.57 (m, 1H), 2.41 - 1.87 (m, 6H), 1.20(t, J = 7.2 Hz, 3H)
[0349] Step 2: Ethyl 4-(4-amino-6-(4-nitrophenyl)pyrimidin-5-yl)cyclohexyl-3-ene-1-carboxylate (55D)
[0350] Compound 55B (1.1 g, 3.9 mmol), 4-nitrophenylboronic acid 55C (0.78 g, 4.7 mmol), tetrakis(triphenylphosphine)palladium (0.45 g, 0.39 mmol), and potassium carbonate (1.1 g, 7.8 mmol) were dissolved in dioxane (15 mL) and water (1.5 mL). After purging with nitrogen three times, the mixture was stirred at 100 °C for 2 hours. The reaction mixture was cooled, and 20 mL of saturated ammonium chloride solution was added, followed by extraction with 40 mL of ethyl acetate. The resulting organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (eluting phase: petroleum ether containing 50% ethyl acetate) to give compound 55D (0.39 g, yield: 27%).
[0351] MS (ESI+) m / z = 368.2[M+H].
[0352] Step 3: Ethyl 4-(4-amino-6-(4-aminophenyl)pyrimidin-5-yl)cyclohexyl-3-ene-1-carboxylate (55E)
[0353] Compound 55D (0.36 g, 1.0 mmol) was dissolved in 10 mL of methanol, and iron powder (0.56 g, 10 mmol) and 2 mL of saturated ammonium chloride solution were added. The mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours. The resulting mixture was filtered through diatomaceous earth, and the filter cake was washed with 40 mL of ethyl acetate. 20 mL of saturated sodium chloride solution was added to the filtrate, followed by extraction with another 20 mL of ethyl acetate. The resulting organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (eluting phase: petroleum ether containing 50%-100% ethyl acetate) to give solid 55E (0.21 g, yield: 62%).
[0354] MS (ESI+) m / z = 339.2[M+H].
[0355] Step 4: Ethyl 4-(4-amino-6-(4-(-2-butynylamino)phenyl)pyrimidin-5-yl)cyclohex-3-ene-1-carboxylate (55g)
[0356] Compound 55E (0.21 g, 0.58 mmol) and N,N-diisopropylethylamine (0.23 g, 1.8 mmol) were dissolved in 3 mL of dichloromethane, and 2-butynyl chloride 55F (55 mg, 0.55 mmol) was added at 0°C. The resulting mixture was stirred at 0°C for 1 hour. The resulting reaction solution was concentrated under reduced pressure, and the crude product was subjected to C... 18 Purification was performed by reversed-phase chromatography (elution phase was an aqueous solution containing 5-80% acetonitrile), and the solvent was removed by lyophilization to obtain compound 55G (0.19 g, yield: 81%).
[0357] MS (ESI+) m / z = 405.2[M+H].
[0358] Step 5: 4-(4-amino-6-(4-(-2-butynylamino)phenyl)pyrimidin-5-yl)cyclohex-3-ene-1-carboxylic acid (55H)
[0359] Compound 55G (0.19 g, 0.47 mmol) and lithium hydroxide (23 mg, 0.95 mmol) were mixed in tetrahydrofuran (2 mL) and water (0.5 mL). The resulting mixture was stirred at room temperature for 1 hour, and then dry ice (5 g) was added to the reaction mixture. The mixture was concentrated under reduced pressure to give crude compound 55H (0.24 g).
[0360] MS (ESI+) m / z = 377.2[M+H].
[0361] Step 6: N-(4-(6-amino-5-(4-((S)-2-cyanopyrrolidine-1-carbonyl)cyclohex-1-en-1-yl)pyrimidin-4-yl)phenyl)-2-butynamide (55)
[0362] 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (57 mg, 0.15 mmol) was added to a solution of crude 55H (48 mg, approximately 0.1 mmol) in N,N-dimethylformamide (1 mL), followed by the addition of N,N-diisopropylethylamine (39 mg, 0.3 mmol) and (S)-2-cyanopyrrolidine 55I (20 mg, 0.21 mmol). The resulting solution was stirred at room temperature for 2 hours. The mixture was filtered and purified by preparative high-performance liquid chromatography (Waters Xbridge C18, 20-60% acetonitrile aqueous solution (containing 0.01% ammonia)) to give the title compound 55 (3.6 mg, yield: 7.9%).
[0363] MS (ESI+) m / z = 455.2[M+H].
[0364] 1 H NMR (400 MHz, DMSO-d6) δ 10.76 (s, 1H), 8.31 (s, 1H), 7.62 (d, J =8.6 Hz, 4H), 6.63 (s, 2H), 5.76 (s, 1H), 4.72 (dt, J = 7.6, 3.9 Hz, 1H), 3.69(s, 4H), 2.34 - 2.10 (m, 4H), 2.06 (m, 4H), 1.71 (m, 2H), 1.24 (m, 2H), 0.96(m, 2H).
[0365] Example 18-1
[0366] Following a similar route and steps as in Example 17, compounds 55A in the first step were replaced with different raw materials G in the table below, 2-butynyl chloride 55F was replaced with acryloyl chloride 4B in the fourth step, and 55I was replaced with raw material H in the table below in the sixth step, to synthesize the corresponding compounds 56-59 in the table.
[0367]
[0368]
[0369] Example 18-2
[0370] N-(3-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (60)
[0371]
[0372] Step 1: 2,4-Dichloro-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidine (60B)
[0373] 2,4-Dichloro-5-iodopyrimidine 60A (5.0 g, 18 mmol), compound 1G (6.0 g, 18 mmol), potassium carbonate (5.0 g, 36 mmol), and (diphenylphosphine ferrocene)palladium dichloride (0.70 g, 0.91 mmol) were added to a mixed solvent of dioxane (50 mL) and water (5 mL). After purging with nitrogen three times, the mixture was stirred at 100 °C for 2 hours. The reaction solution was quenched with 20 mL of ammonium chloride and extracted with 100 mL of ethyl acetate. The resulting organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4 / 1-2 / 1) to obtain compound 60B (2.9 g, yield: 45%).
[0374] MS (ESI+) m / z = 351.0[M+H].
[0375] Step 2: 2-Chloro-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-4-(3-nitrophenyl)pyrimidine (60D)
[0376] Compound 60B (2.1 g, 6.0 mmol), 3-nitrophenylboronic acid 60C (1.0 g, 6.0 mmol), potassium carbonate (1.7 g, 12.0 mmol), and tetrakis(triphenylphosphine)palladium (0.35 g, 0.30 mmol) were added to a mixed solvent of dioxane (20 mL) and water (2 mL). After purging with nitrogen three times, the mixture was stirred at 100 °C for 2 hours. The reaction solution was quenched with 20 mL of ammonium chloride and then extracted with 50 mL of ethyl acetate. The resulting organic phase was concentrated to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1-1 / 1) to obtain compound 60D (1.0 g, yield: 38%).
[0377] MS (ESI+) m / z = 438.1[M+H].
[0378] 1 H NMR (400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.39 - 8.31 (m, 2H), 7.87 (d, J = 8.0 Hz, 1H), 7.79 - 7.71 (m, 1H), 7.53 -7.43 (m, 2H), 7.30 - 7.20 (m, 2H), 2.48 - 2.44 (m, 3H).
[0379] Step 3: 5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-N-(1-methyl-1H-pyrazol-4-yl)-4-(3-nitrophenyl)pyrimidin-2-amine (60F)
[0380] Compound 60D (0.40 g, 0.91 mmol), 1-methyl-1H-pyrazole-4-amine 60E (0.17 g, 1.8 mmol), cesium carbonate (0.88 g, 2.7 mmol), 1,1'-binaphthyl-2,2'-bis(diphenylphosphine) (57 mg, 0.091 mmol), and palladium acetate (20 mg, 0.091 mmol) were added to dioxane (20 mL). After purging with nitrogen three times, the mixture was stirred at 100 °C for 2 hours. The reaction solution was quenched with 20 mL of ammonium chloride and extracted with 50 mL of ethyl acetate. The resulting organic phase was concentrated to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1-0 / 1) to give compound 60F (0.20 g, yield: 44%).
[0381] MS (ESI+) m / z = 499.1[M+H].
[0382] Step 4: 4-(3-aminophenyl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (60g)
[0383] Compound 60F (0.18 g, 0.36 mmol) was dissolved in 5 mL of methanol, and iron powder (0.2 g, 3.6 mmol) and 1 mL of saturated ammonium chloride solution were added. The mixture was stirred for 16 hours at room temperature under a nitrogen atmosphere. The resulting mixture was filtered through diatomaceous earth, and the filter cake was washed with 20 mL of ethyl acetate. 10 mL of saturated sodium chloride solution was added to the filtrate, followed by extraction with another 20 mL of ethyl acetate. The resulting organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was analyzed by C... 18 Purified by reversed-phase column chromatography (mobile phase: 5-80% acetonitrile aqueous solution) and lyophilized to remove solvent, yielding 60g (80 mg, yield: 47%) of solid.
[0384] MS (ESI+) m / z = 469.2[M+H].
[0385] Step 5: N-(3-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (60)
[0386] Compound 60G (70 mg, 0.15 mmol) and triethylamine (45 mg, 0.45 mmol) were dissolved in dichloromethane (5 mL), and a dichloromethane solution of acryloyl chloride 4B (13 mg, 0.15 mmol, 150 μL, 1.0 mol / L) was slowly added dropwise at 0°C. The resulting mixture was stirred at 0°C for 1 hour. The solvent was removed by vacuum distillation, and the residue was purified by preparative chromatography (Phenomenex Luna C18 150*25mm*10µm, eluent 3%-55% acetonitrile-water) to give a white solid, title compound 60 (20 mg, yield: 26%).
[0387] MS (ESI+) m / z = 523.2[M+H].
[0388] 1 H NMR(400 MHz, DMSO-d6) δ 10.27 (s, 1H), 9.75 (s, 1H), 8.53 (s, 1H), 8.46 (d, J = 4.8 Hz, 1H), 8.43 - 7.80 (m, 2H), 7.60 (s, 1H), 7.53 (s, 1H),7.33 - 7.20 (m, 3H), 7.18 (d, J = 5.2 Hz, 1H), 7.03 (d, J = 8.0 Hz, 1H), 6.91(d, J = 7.6 Hz, 1H), 6.53 - 6.39 (m, 1H), 6.35 - 6.19 (m, 1H), 5.77 (d, J =11.2 Hz, 1H), 3.84 (s, 3H), 2.41 (s, 3H).
[0389] Example 19
[0390] N-(3-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)methacryloylamide (61)
[0391]
[0392] Using compound 60G as a starting material, compound 61 was synthesized by replacing acryloyl chloride 4B with 61A using a similar synthesis method to step 5 in Example 18-2.
[0393] MS (ESI+) m / z = 537.1 [M+H].
[0394] 1 H NMR (400 MHz, DMSO-d6) δ 9.94 ( s, 1H), 9.76 (s, 1H), 8.52 (s, 1H), 8.46 (d, J = 5.2 Hz, 1H), 8.0 (s, 2H), 7.60 (s, 1H), 7.51 (s, 1H), 7.32 -7.16 (m, 4H), 7.03 (d, J = 8.0 Hz, 1H), 6.86 (d, J = 6.8 Hz, 1H), 5.82 (s,1H), 5.54 (s, 1H), 3.85 (s, 3H), 2.41 (s, 3H), 1.96 (s, 3H).
[0395] Example 20
[0396] N-(3-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)propionylamide (62)
[0397]
[0398] Using compound 60G as a starting material, compound 62 was synthesized by replacing acryloyl chloride 4B with 62A using a similar synthesis method as step 5 in Example 18-2.
[0399] MS (ESI+) m / z = 525.1[M+H].
[0400] 1 H NMR (400 MHz, DMSO-d6) δ 9.98 (s, 1H), 9.73 (s, 1H), 8.52 (s, 1H), 8.47 (d, J = 5.2 Hz, 1H), 8.09 (s, 2H), 7.52 - 7.51 (m, 1H), 7.52 (s, 1H),7.36 - 7.13 (m, 4H), 7.02 (d, J = 8.0 Hz, 1H), 6.84 (d, J = 7.2 Hz, 1H),3.84 (s, 3H), 2.42 (s, 3H), 2.38 - 2.29 (m, 2H), 1.19 - 1.04 (m, 3H).
[0401] Example 21
[0402] 2-Fluoro-N-(3-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (63)
[0403]
[0404] Using compound 60G as the starting material, a similar synthesis method to step 2 in Example 7 was adopted, with 7B replaced by 63A and bis(2-oxazolyl)phosphine chloride replaced by 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate. The reaction was carried out at room temperature for 1 hour to synthesize compound 63.
[0405] MS (ESI+) m / z = 541.1[M+H].
[0406] 1 H NMR (400 MHz, DMSO-d6) δ 10.44 (d, J = 4.4 Hz, 1H), 9.77 (s, 1H), 8.53 (s, 1H), 8.46 (d, J = 5.2 Hz, 1H), 8.13 (s, 2H), 7.66 (d, J = 7.2 Hz,1H), 7.53 (s, 1H), 7.34 - 7.15 (m, 4H), 7.09 - 6.90 (m, 2H), 5.83 - 5.63 (m,1H), 5.45 (dd, J = 3.6, 15.5 Hz, 1H), 3.84 (s, 3H), 2.41 (s, 3H).
[0407] Example 22
[0408] N-(3-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)2-methylphenyl)acryloylamide (64)
[0409]
[0410] Using similar synthetic steps and methods as in the second step and beyond of Example 18-2, 64A was used to replace 60C to synthesize compound 64.
[0411] MS (ESI+) m / z = 537.2[M+H].
[0412] 1H NMR (400 MHz, DMSO-d6) δ 9.76 (s, 1H), 9.52 (s, 1H), 8.59 (s, 1H), 8.44 (d, J = 5.2 Hz, 1H), 8.02 - 7.70 (m, 1H), 7.64 - 7.43 (m, 2H), 7.28 -7.19 (m, 2H), 7.16 (d, J = 5.2 Hz, 1H), 7.14 - 7.05 (m, 2H), 6.94 (d, J = 8.0Hz, 1H), 6.52 (dd, J = 10.4, 16.6 Hz, 1H), 6.23 (d, J = 17.2 Hz, 1H), 5.73(d, J = 10.4 Hz, 1H), 3.80 (s, 3H), 2.39 (s, 3H), 1.92 (s, 3H).
[0413] Example 23
[0414] N-(3-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)2-methoxyphenyl)acryloylamide (65)
[0415]
[0416] Using similar synthetic steps and methods as in the second step and subsequent steps of Example 18-2, 60C was replaced with 65A to synthesize compound 65.
[0417] MS (ESI+) m / z = 553.2[M+H].
[0418] 1H NMR (400 MHz, DMSO-d6) δ 9.79 (s, 1H), 9.57 (s, 1H), 8.59 (s, 1H), 8.44 (d, J = 5.2 Hz, 1H), 8.18 ( d, J = 6.3 Hz, 1H), 7.88 ( s, 1H), 7.53 (s,1H), 7.24 - 7.14 (m, 5H), 6.97 (dd, J = 1.6, 8.4 Hz, 1H), 6.75 (dd, J = 10.0,17.0 Hz, 1H), 6.25 (dd, J = 1.8, 16.8 Hz, 1H), 5.75 - 5.68 (m, 1H), 3.81 (s,3H), 3.44 (s, 3H), 2.38 (s, 3H).
[0419] Example 24
[0420] N-(3-(2-((1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)phenyl)acryloylamide (66)
[0421]
[0422] Using similar synthetic steps and methods as in the third step and beyond of Example 18-2, 60E was replaced with 66A to synthesize compound 66.
[0423] MS (ESI+) m / z = 580.3[M+H].
[0424] Example 25
[0425] N-(3-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-(1-methylpyrrolidone-3-yl)-1H-pyrazole-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (67)
[0426]
[0427] Using similar synthetic steps and methods as in the third step and beyond of Example 18-2, 60E was replaced with 67A to synthesize compound 67.
[0428] MS (ESI+) m / z = 592.3[M+H].
[0429] 1H NMR (400 MHz, DMSO-d6) δ 10.27 (t, J = 5.2 Hz, 1H), 9.77 (s, 1H), 8.55 (s, 1H), 8.47 (d, J = 5.2 Hz, 1H), 8.22 (s, 1H), 7.67 - 7.59 (m, 1H),7.57 (s, 1H), 7.32 - 7.21 (m, 3H), 7.19 (d, J = 4.8 Hz, 1H), 7.03 (d, J = 6.8Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.52 - 6.40 (m, 1H), 6.33 - 6.24 (m, 1H),5.78 (d, J = 11.6 Hz, 1H), 4.91 (s, 1H), 2.87 - 2.80 (m, 4H), 2.41 (s, 3H), 2.26 (s, 5H), 2.05 ( d, J = 6.4 Hz, 1H).
[0430] Example 26
[0431] N-(3-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (68)
[0432]
[0433] Using similar synthetic steps and methods as in the third step and beyond of Example 18-2, 60E was replaced with 68A to synthesize compound 68.
[0434] MS (ESI+) m / z = 605.3[M+H].
[0435] Example 27
[0436] N-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (69)
[0437]
[0438] Step 1: 2,5-Dichloro-4-(4-nitrophenyl)pyrimidine (69B)
[0439] 2,4,5-Trichloropyrimidine 69A (1.8 g, 10 mmol), p-nitrophenylboronic acid 55C (1.7 g, 10 mmol), potassium carbonate (2.8 g, 20 mmol), and (diphenylphosphine ferrocene)palladium dichloride (0.35 g, 0.46 mmol) were added to a mixed solvent of dioxane (20 mL) and water (2 mL). After purging with nitrogen three times, the mixture was stirred at 70 °C for 2 hours. The reaction solution was quenched with 20 mL of ammonium chloride and extracted with 100 mL of ethyl acetate. The resulting organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4 / 1-2 / 1) to give compound 69B (1.7 g, yield: 63%).
[0440] MS (ESI+) m / z = 270.0[M+H].
[0441] Step 2: 5-Chloro-N-(1-Methyl-1H-pyrazol-4-yl)-4-(4-nitrophenyl)pyrimidin-2-amine (69C)
[0442] Compound 69B (0.24 g, 0.91 mmol), 1-methyl-1H-pyrazole-4-amine 60E (0.17 g, 1.8 mmol), cesium carbonate (0.88 g, 2.7 mmol), 1,1'-binaphthyl-2,2'-bis(diphenylphosphine) (57 mg, 0.091 mmol), and palladium acetate (20 mg, 0.091 mmol) were added to dioxane (20 mL). After purging with nitrogen three times, the mixture was stirred at 100°C for 2 hours. The reaction solution was quenched with 20 mL of ammonium chloride and extracted with 50 mL of ethyl acetate. The resulting organic phase was concentrated to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1-0 / 1) to give compound 69C (0.20 g, yield: 67%).
[0443] MS (ESI+) m / z = 331.0[M+H].
[0444] Step 3: 5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-N-(1-methyl-1H-pyrazol-4-yl)-4-(4-nitrophenyl)pyrimidin-2-amine (69D)
[0445] Compound 69C (0.20 g, 0.61 mmol), compound 1G (0.20 g, 0.61 mmol), potassium carbonate (170 mg, 1.2 mmol), palladium acetate (13 mg, 0.06 mmol), and tricyclohexylphosphine (34 mg, 0.12 mmol) were added to a mixed solvent of dioxane (20 mL) and water (2 mL). After purging with nitrogen three times, the mixture was stirred at 100 °C for 2 hours. The reaction solution was quenched with 20 mL of ammonium chloride and then extracted with 50 mL of ethyl acetate. The resulting organic phase was concentrated to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1-0 / 1) to obtain compound 69D (0.13 g, yield: 41%).
[0446] MS (ESI+) m / z = 499.1[M+H].
[0447] Step 4: 4-(4-aminophenyl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (69E)
[0448] Compound 69D (0.13 g, 0.26 mmol) was dissolved in 5 mL of methanol, and iron powder (0.2 g, 3.6 mmol) and 1 mL of saturated ammonium chloride solution were added. The mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours. The resulting mixture was filtered through diatomaceous earth, and the filter cake was washed with 20 mL of ethyl acetate. 10 mL of saturated sodium chloride solution was added to the filtrate, and another 20 mL of ethyl acetate was added for extraction. The resulting organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by C18 reversed-phase column (mobile phase: 5-80% acetonitrile aqueous solution) and lyophilized to remove the solvent to obtain solid 69E (42 mg, yield: 34%).
[0449] MS (ESI+) m / z = 469.2[M+H].
[0450] Step 5: N-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (69)
[0451] Compound 69E (42 mg, 0.09 mmol) and triethylamine (18 mg, 0.18 mmol) were dissolved in dichloromethane (5 mL), and a dichloromethane solution of acryloyl chloride 4B (7.6 mg, 0.085 mmol, 85 μL, 1.0 mol / L) was slowly added dropwise at 0°C. The resulting mixture was stirred at 0°C for 1 hour. The solvent was removed by vacuum distillation, and the residue was purified by preparative chromatography (Phenomenex Luna C18 150*25mm*10µm, eluent 3%-55% acetonitrile-water) to give a white solid, title compound 69 (18 mg, yield: 38%).
[0452] MS (ESI+) m / z = 523.2[M+H].
[0453] 1 H NMR (400 MHz, DMSO-d6) δ 10.30 (s, 1H), 9.72 (s, 1H), 8.49 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 7.92 (s, 1H), 7.67 (d, J = 8.4 Hz, 2H), 7.49 (d, J= 60.8 Hz, 3H), 7.31 (t, J = 8.4 Hz, 1H), 7.26 - 7.21 (m, 1H), 7.19 (d, J =5.1 Hz, 1H), 7.05 - 6.98 (m, 1H), 6.44 (dd, J = 16.9, 10.1 Hz, 1H), 6.27 (dd,J = 16.9, 2.0 Hz, 1H), 5.78 (dd, J = 10.0, 2.1 Hz, 1H), 3.82 (s, 3H), 2.43(s, 3H).
[0454] Example 28
[0455] N-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-6-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (70)
[0456]
[0457] Using similar synthesis steps and methods as in step 3 and beyond of Example 27, 69A was replaced with 70A to synthesize compound 70.
[0458] MS (ESI+) m / z = 537.2[M+H].
[0459] 1 H NMR (400 MHz, DMSO-d6) δ 10.17 (s, 1H), 9.54 (s, 1H), 8.43 (d, J =5.0 Hz, 1H), 7.57 - 7.50 (m, 2H), 7.48 (s, 1H), 7.24 (t, J = 8.3 Hz, 1H), 7.18 (dd, J = 11.4, 2.0 Hz, 1H), 7.13 (d, J = 5.1 Hz, 1H), 6.95 (d, J = 8.1Hz, 1H), 6.35 (dd, J = 16.8, 10.1 Hz, 1H), 6.19 (dd, J = 17.0, 2.0 Hz, 1H),5.70 (dd, J = 10.1, 2.1 Hz, 1H), 3.74 (s, 3H), 2.35 (s, 3H), 2.22 (s, 3H).
[0460] Example 29
[0461] N-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-6-amino-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (71)
[0462]
[0463] Using similar synthesis steps and methods as in step 3 and beyond of Example 27, 69A was replaced with 71A to synthesize compound 71.
[0464] MS (ESI+) m / z = 538.2[M+H].
[0465] 1H NMR (400 MHz, DMSO-d6) δ 10.22 (s, 1H), 8.50 - 8.48 (m, 1H), 8.19- 8.08 (m, 1H), 7.74 - 7.51 (m, 4H), 7.33 - 7.25 (m, 3H), 7.20 - 7.19 (m,2H), 6.98 - 6.96 (m, 1H), 6.69 - 6.66 (m, 2H), 6.45 - 6.38 (m, 1H), 6.28 -6.23 (m, 1H), 5.57 - 5.76 (m, 1H), 3.80 (s, 3H), 2.42 (s, 3H).
[0466] Example 30
[0467] N-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)but-2-yneamide (72)
[0468]
[0469] Using compound 69E as a raw material, and employing a method similar to step 5 in Example 27, acryloyl chloride 4B was replaced with 2-butynyl chloride 55F to synthesize compound 72.
[0470] MS (ESI+) m / z = 535.2[M+H].
[0471] 1 H NMR (400 MHz, DMSO-d6) δ 10.71 (s, 1H), 9.65 (s, 1H), 8.41 (d, J =5.0 Hz, 2H), 7.85 (s, 1H), 7.57 - 7.44 (m, 3H), 7.32 (s, 2H), 7.23 (t, J =8.4 Hz, 1H), 7.19 - 7.08 (m, 2H), 6.97 - 6.89 (m, 1H), 3.75 (s, 3H), 2.36 (s,3H), 1.98 (s, 3H).
[0472] Example 31
[0473] 2-Fluoro-N-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (73)
[0474]
[0475] Using compound 69E as a starting material, and employing a similar synthetic method to the second step in Example 7, 7B was replaced with 63A, and bis(2-oxazolyl)phosphine chloride was replaced with 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate to synthesize compound 73.
[0476] MS (ESI+) m / z = 541.1[M+H].
[0477] 1 H NMR (400 MHz, DMSO-d6) δ 10.43 (s, 1H), 9.74 (s, 1H), 8.51 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 7.92 (s, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.57 (s,1H), 7.43 (s, 2H), 7.31 (t, J = 8.4 Hz, 1H), 7.26 - 7.21 (m, 1H), 7.19 (d, J= 5.1 Hz, 1H), 7.01 (dd, J = 8.1, 1.8 Hz, 1H), 5.73 (dd, J = 47.6, 3.7 Hz, 1H), 5.46 (dd, J = 15.6, 3.7 Hz, 1H), 3.82 (s, 3H), 2.43 (s, 3H).
[0478] Example 32
[0479] N-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (74)
[0480]
[0481] Using a similar route and steps as in Example 27, 74B was synthesized by replacing 60E in the second step with 74A.
[0482] Compound 74B (27 mg, 0.039 mmol) was dissolved in 2 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added at 0°C. The resulting mixture was stirred at 0°C for 1 hour. The solvent and trifluoroacetic acid were removed by concentration under reduced pressure, and the crude product was purified by preparative chromatography (Phenomenex Luna C). 18 Compound 74 (8.7 mg, yield: 37%) was obtained by eluing acetonitrile-water (150*25mm*10um). The eluent was 3%-55% acetonitrile-water.
[0483] MS (ESI+) m / z = 592.3 [M+H].
[0484] Example 33
[0485] 2-Fluoro-N-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (75)
[0486]
[0487] Using a similar route and steps as in Example 27, but replacing 60E in the second step with 74A, compound 75B can be synthesized. Compound 75 can then be synthesized from compound 75B through two further reaction steps.
[0488] Step 1: 4-(4-((5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-4-(4-(2-fluoroacryloylamino)phenyl)pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-carboxylic acid tert-butyl ester (75C)
[0489] Compound 75B (56 mg, 0.088 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (38 mg, 0.10 mmol), and 2-fluoroacrylic acid (18 mg, 0.20 mmol) were mixed in a solution of dichloromethane, followed by the addition of N,N-diisopropylethylamine (39 mg, 0.30 mmol). The resulting solution was stirred at 0°C for 1 hour. The mixture was filtered and then subjected to C... 18 Reversed-phase chromatography (elution phase: 20-80% aqueous acetonitrile) was used to purify compound 75C (26 mg, yield: 42%).
[0490] MS (ESI+) m / z = 710.3 [M+H].
[0491] Step 2: 2-Fluoro-N-(4-(5-(3-Fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (75)
[0492] Compound 75C (26 mg, 0.037 mmol) was dissolved in 2 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added at 0°C. The resulting mixture was stirred at 0°C for 1 hour. The solvent and trifluoroacetic acid were removed by concentration under reduced pressure, and the crude product was purified by preparative chromatography (Phenomenex Luna C). 18 Compound 75 (6.1 mg, yield: 27%) was obtained by eluing acetonitrile-water (150*25mm*10um, elution phase: 3%-55% acetonitrile-water).
[0493] MS (ESI+) m / z = 610.2 [M+H].
[0494] Example 34
[0495] N-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3-methylphenyl)acryloylamide (76)
[0496]
[0497] Following the synthetic route and method of Example 27, compound 76 was synthesized by replacing 55C with 76A.
[0498] MS (ESI+) m / z = 537.2 [M+H].
[0499] 1H NMR (400 MHz, DMSO-d6) δ 10.19 (s, 1H), 9.73 (s, 1H), 8.58 (s,1H), 8.46 (d, J = 5.0 Hz, 1H), 7.70 (m, 1H), 7.49 (m, 3H), 7.23 (t, J = 8.4Hz, 1H), 7.15 (m, 2H), 7.12 (dd, J = 11.7, 1.8 Hz, 1H), 6.89 (m, 1H), 6.43(dd, J = 17.0, 10.1 Hz, 1H), 6.26 (d, J = 18.8 Hz, 1H), 5.76 (d, J = 12.0 Hz,1H), 3.80 (s, 3H), 2.40 (s, 3H), 2.03 (s, 3H).
[0500] Example 35
[0501] N-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3-fluorophenyl)acryloylamide (77)
[0502]
[0503] Following the synthetic route and method of Example 27, 77 was synthesized by replacing 55C with 77A.
[0504] MS (ESI+) m / z = 541.2 [M+H].
[0505] 1H NMR (400 MHz, DMSO-d6) δ 12.40 (s, 1H), 9.20 (s, 1H), 9.07 (d, J =6.6 Hz, 1H), 8.49 (d, J = 5.0 Hz, 1H), 7.92 (s, 1H), 7.83 – 7.55 (m, 2H), 7.39 (t, J = 8.4 Hz, 1H), 7.32 (dd, J = 11.5, 2.1 Hz, 1H), 7.24 – 7.13 (m,2H), 5.58 (d, J = 3.5 Hz, 0.5H), 5.46 (d, J = 3.5 Hz, 0.5H), 5.27 (dd, J =15.6, 3.5 Hz, 1H), 4.58 – 4.51 (m, 1H), 4.12 – 4.00 (m, 2H), 3.86 – 3.74 (m, 2H), 2.42 (s, 3H).
[0506] Example 36
[0507] 2-Fluoro-N-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3-methylphenyl)acryloylamide (78)
[0508]
[0509] Following the synthetic route and method of Example 27, 55C was replaced with 76A, and acryloyl chloride 4B was replaced with 2-fluoroacryloyl chloride to synthesize compound 78.
[0510] MS (ESI+) m / z = 555.2 [M+H].
[0511] 1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.75 (s, 1H), 8.59 (s,1H), 8.47 - 8.45 (m, 1H), 7.61 - 7.9 (m, 2H), 7.52 (s, 1H), 7.25 - 7.11 (m,5H), 6.94 - 6.92 (m, 1H), 5.78 - 5.77 (m, 0.5H), 5.66 - 5.65 (m, 0.5H), 5.47- 5.42 (m, 1H), 3.80 (s, 3H), 2.40 (s, 3H).
[0512] Example 37
[0513] N-(4-(5-(4-((S)-2-cyanopyrrolidine-1-carbonyl)cyclohex-1-en-1-yl)-2-((1-methyl-1H-pyrazole-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (79)
[0514]
[0515] Following the synthetic route and method of Example 27, 55A was used to replace 1G to synthesize compound 79A. Then, 55G in Example 17 was replaced with compound 79A, and compound 79 was synthesized by following the synthetic steps and methods of steps five and six in Example 17.
[0516] MS (ESI+) m / z = 523.2 [M+H].
[0517] 1 H NMR (400 MHz, DMSO-d6) δ 10.36 (d, J = 3.5 Hz, 1H), 9.49 (s, 1H), 8.20 (s, 1H), 7.88 (d, J = 4.7 Hz, 1H), 7.84 - 7.70 (m, 4H), 7.52 (s, 1H), 6.54 - 6.38 (m, 1H), 6.35 - 6.20 (m, 1H), 5.86 - 5.73 (m, 2H), 4.73 (ddd, J =7.4, 5.2, 3.6 Hz, 1H), 3.80 (s, 3H), 3.74 - 3.61 (m, 1H), 3.51 (dt, J = 16.3,7.6 Hz, 1H), 2.68 (d, J = 9.1 Hz, 1H), 2.41 - 1.63 (m, 10H).
[0518] Example 38
[0519] N-(3-(5-(4-((S)-2-cyanopyrrolidine-1-carbonyl)cyclohex-1-en-1-yl)-2-((1-methyl-1H-pyrazole-4-yl)amino)pyrimidin-4-yl)phenyl)acryloylamide (80)
[0520]
[0521] Following the synthetic route and method of Examples 18-2, 1G was replaced with 55A to synthesize compound 80A. Then, 55G in Example 17 was replaced with compound 80A, and compound 80 was synthesized using the synthetic steps and methods of steps five and six in Example 17.
[0522] MS (ESI+) m / z = 523.2 [M+H].
[0523] Example 39
[0524] N-(1-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)azacyclobutane-3-yl)acryloylamide (81)
[0525]
[0526] Step 1 (1-(2-chloro-5-bromopyrimidin-4-yl)azacyclobutane-3-yl)tert-butyl carbamate (81C)
[0527] 2,4-Dichloro-5-bromopyrimidine 81A (2.3 g, 10 mmol), 3-tert-butoxycarbonyl-aminoazacyclobutane 81B (1.7 g, 10 mmol), and N,N-diisopropylethylamine (2.6 g, 20 mmol) were mixed in 25 mL of dioxane. The resulting mixture was stirred at 80 °C for 1 hour and then concentrated under reduced pressure. The crude product 81C (6.6 g, approximately 10 mmol) was used directly in the next step.
[0528] MS (ESI+) m / z = 363.1, 365.1[M+H].
[0529] Step 2: (1-(2-chloro-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)azacyclobutane-3-yl)tert-butyl carbamate (81D)
[0530] Compound 81C (3.3 g, crude, approx. 5.0 mmol), compound 1G (2.0 g, 6.0 mmol), potassium carbonate (2.8 g, 20 mmol), and (diphenylphosphine ferrocene)palladium dichloride (0.38 g, 0.5 mmol) were added to a mixed solvent of dioxane (30 mL) and water (3 mL). After purging with nitrogen three times, the mixture was stirred at 100 °C for 2 hours. The reaction solution was quenched with 20 mL of ammonium chloride and extracted with 100 mL of ethyl acetate. The resulting organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4 / 1-2 / 1) to obtain compound 81D (1.7 g, yield: 71%).
[0531] MS (ESI+) m / z = 487.1[M+H].
[0532] Step 3 (1-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)azacyclobutane-3-yl) tert-butyl carbamate (81E)
[0533] Compound 81D (0.49 g, 1.0 mmol), 1-methyl-1H-pyrazole-4-amine 60E (0.17 g, 1.8 mmol), cesium carbonate (0.88 g, 2.7 mmol), 1,1'-binaphthyl-2,2'-bis(diphenylphosphine) (62 mg, 0.10 mmol), and palladium acetate (22 mg, 0.10 mmol) were added to dioxane (20 mL). After purging with nitrogen three times, the mixture was stirred at 100 °C for 2 hours. The reaction solution was quenched with 20 mL of ammonium chloride and extracted with 50 mL of ethyl acetate. The resulting organic phase was concentrated to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1-0 / 1) to give compound 81E (0.37 g, yield: 67%).
[0534] MS (ESI+) m / z = 548.2[M+H].
[0535] Step 4: 4-(3-aminoazacyclobutane-1-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (81F)
[0536] Compound 81E (0.37 g, 0.67 mmol) was dissolved in 5 mL of dichloromethane, and 1 mL of trifluoroacetic acid was slowly added at 0°C. The resulting solution was stirred at 0°C for 1 hour, then concentrated under reduced pressure to obtain the crude product. The crude product was subjected to reverse-phase C2... 18 Compound 81F (0.26 g, yield: 87%) was purified by chromatographic column (elution phase: 5-75% acetonitrile aqueous solution (containing 8 mmol / L NH3)).
[0537] MS (ESI+) m / z = 448.2[M+H].
[0538] Step 5: N-(1-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)azacyclobutane-3-yl)acryloylamide (81)
[0539] Compound 81F (45 mg, 0.10 mmol) and triethylamine (20 mg, 0.20 mmol) were dissolved in dichloromethane (2 mL), and a dichloromethane solution of acryloyl chloride 4B (9.0 mg, 0.1 mmol, 100 μL, 1.0 mol / L) was slowly added dropwise at 0°C. The resulting mixture was stirred at 0°C for 1 hour. The solvent was removed by vacuum distillation, and the residue was purified by preparative chromatography (Phenomenex Luna C). 18 150*25mm*10um, with 5%-75% acetonitrile-water as the eluent, yielded a white solid, title compound 81 (26 mg, yield: 52%).
[0540] MS (ESI+) m / z = 502.2[M+H].
[0541] 1H NMR (400 MHz, DMSO-d6) δ 9.21 (s, 1H), 8.72 (d, J = 6.8 Hz, 1H), 8.49 (d, J = 5.0 Hz, 1H), 7.92 (s, 1H), 7.83 (s, 1H), 7.49 (s, 1H), 7.39 (t,J = 8.3 Hz, 1H), 7.32 (dd, J = 11.4, 2.0 Hz, 1H), 7.24 - 7.13 (m, 2H), 6.23 -6.01 (m, 2H), 5.61 (dd, J = 9.6, 2.6 Hz, 1H), 4.51 (d, J = 7.4 Hz, 1H), 4.08(s, 2H), 3.80 (s, 3H), 3.66 (s, 2H), 2.42 (s, 3H).
[0542] Example 40
[0543] N-(1-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)azacyclobutane-3-yl)-2-butynamide (82)
[0544]
[0545] Using compound 81F as a raw material, and employing a method similar to step 5 in Example 27, acryloyl chloride 4B was replaced with 2-butynyl chloride 55F to synthesize compound 82.
[0546] MS (ESI+) m / z = 514.2[M+H].
[0547] 1H NMR (400 MHz, DMSO-d6) δ 9.13 (s, 1H), 9.05 (d, J = 6.7 Hz, 1H), 8.42 (d, J = 5.0 Hz, 1H), 7.84 (s, 1H), 7.75 (s, 1H), 7.42 (s, 1H), 7.31 (t,J = 8.4 Hz, 1H), 7.24 (dd, J = 11.5, 2.1 Hz, 1H), 7.14 - 7.06 (m, 2H), 4.37(s, 1H), 4.07 - 3.82 (m, 2H), 3.73 (s, 3H), 3.67 - 3.44 (m, 2H), 2.35 (s, 3H), 1.88 (s, 3H).
[0548] Example 41
[0549] 2-Fluoro-N-(1-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)azacyclobutane-3-yl)acryloylamide (83)
[0550]
[0551] Compound 81F (40 mg, 0.088 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (38 mg, 0.10 mmol), and 2-fluoroacrylate 63A (18 mg, 0.20 mmol) were mixed in a dichloromethane solution, followed by the addition of N,N-diisopropylethylamine (39 mg, 0.30 mmol). The resulting solution was stirred at 0°C for 1 hour. The mixture was filtered and then subjected to C... 18 Reversed-phase chromatography (elution phase: 20-70% aqueous acetonitrile) yielded compound 83 (21 mg, yield: 46%).
[0552] MS (ESI+) m / z = 520.2[M+H].
[0553] 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 9.07 (d, J = 6.9 Hz, 1H), 8.48 (d, J = 5.0 Hz, 1H), 7.92 (s, 1H), 7.83 (s, 1H), 7.49 (s, 1H), 7.39 (t,J = 8.4 Hz, 1H), 7.31 (dd, J = 11.4, 2.0 Hz, 1H), 7.23 - 7.13 (m, 2H), 5.52(dd, J = 47.9, 3.5 Hz, 1H), 5.27 (dd, J = 15.6, 3.5 Hz, 1H), 4.58 (d, J = 7.4Hz, 1H), 4.06 (s, 2H), 3.94 - 3.46 (m, 5H), 2.42 (s, 3H).
[0554] Example 42
[0555] Following a similar route and steps as in Example 39, replacing compound 81B in the first step with raw material I from the table below will synthesize compounds 84-117. Similarly, following a similar route and steps as in Example 39, when replacing compound 81B in the first step with 118A and 119A from raw material I to synthesize compounds 118-119, the concentration of trifluoroacetic acid in the reaction solution needs to be increased to 50% in the fourth step.
[0556]
[0557]
[0558]
[0559]
[0560]
[0561]
[0562]
[0563]
[0564]
[0565]
[0566]
[0567]
[0568]
[0569] 117A and 118A in raw material I can be synthesized through the following steps:
[0570]
[0571] Step 1: 1-(tert-butyl)-3-methyl-3-((S)-1-(((R)-tert-butylsulfinyl)amino)ethyl)azacyclobutyl-1,3-dicarboxylic acid ester (117D)
[0572] Compounds 117B (4.4 g, 20 mmol) and 117C (1.5 g, 10 mmol) were dissolved in 50 mL of anhydrous tetrahydrofuran, and the resulting solution was cooled to -78°C. A solution of hexamethyldisilamide lithium (1.0 M tetrahydrofuran solution, 20 mL, 20 mmol) was slowly added dropwise with stirring, and the mixture was stirred continuously at -78°C for 3 hours. The reaction mixture was quenched with 10 mL of saturated ammonium chloride solution, and then slowly heated to room temperature. 100 mL of ethyl acetate and 50 mL of saturated ammonium chloride solution were added to the resulting mixture. The resulting organic phase was separated, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 10 / 1-1 / 1) to give compound 117D (2.1 g, yield: 58%).
[0573] MS (ESI+) m / z = 363.2[M+H].
[0574] Step 2: 3-((S)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-3-(hydroxymethyl)azacyclobutyl-1-carboxylic acid tert-butyl ester (117E)
[0575] Compound 117D (2.1 g, 5.8 mmol) was dissolved in 40 mL of anhydrous tetrahydrofuran, and the resulting solution was cooled to 0°C. Lithium aluminum hydride (0.38 g, 10 mmol) was slowly added to the reaction solution, and the mixture was stirred at 0°C for 2 hours. 10 g of sodium sulfate decahydrate was added to the resulting reaction solution, and the mixture was stirred at 0°C for 1 hour, then slowly raised to room temperature and stirred for another 16 hours. The resulting mixture was filtered under reduced pressure, and the filter cake was washed with 50 mL of ethyl acetate. The filtrate was concentrated to obtain a crude product, which was purified by silica gel column chromatography (eluting phase: dichloromethane containing 3% methanol) to give the major product 117E (1.2 g, 62% yield).
[0576] MS (ESI+) m / z = 335.2[M+H].
[0577] Step 3: (S)-6-((R)-tert-butylsulfinyl)-5-methyl-2,6-diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (117F)
[0578] Crude compound 117E (1.2 g, 3.6 mmol) and p-toluenesulfonyl chloride (1.03 g, 5.4 mmol) were dissolved in 20 mL of anhydrous tetrahydrofuran. Sodium hydride (0.7 g, 60%, 17.4 mmol) was slowly added at 0°C. The resulting mixture was stirred at 0°C for 2 hours, and then quenched with 20 mL of water. The resulting reaction solution was extracted three times with 30 mL of ethyl acetate. The separated organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 10 / 1-1 / 1) to give compound 117F (1.0 g, yield: 88%).
[0579] MS (ESI+) m / z = 317.2 [M+H].
[0580] Step 4: (R)-5-methyl-2,6-diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (117A) and (R)-2-((S)-tert-butylsulfinyl)-1-methyl-2,6-diazaspiro[3.3]heptane (118A)
[0581] Compound 117F (0.63 g, 2.0 mmol) was dissolved in 5 mL of dichloromethane, and 0.5 mL of trifluoroacetic acid was added at 0°C. The resulting reaction solution was stirred at 0°C for 1 hour. The reaction solution was concentrated under reduced pressure at 0°C, and the crude product was analyzed by C... 18 Purification was performed by reversed-phase column chromatography (mobile phase: 0-60% acetonitrile aqueous solution) to give compounds 117A (63 mg, yield: 15%) and 118A (122 mg, yield: 28%).
[0582] Compound 117A MS (ESI+) m / z = 213.2 [M+H].
[0583] Compound 118A MS (ESI+) m / z = 217.2 [M+H].
[0584] Using a similar synthetic method and steps to compound 118A, 119A was synthesized by replacing 117C with 119C.
[0585]
[0586] MS (ESI+) m / z = 217.2[M+H].
[0587] Example 43
[0588] By using methods and steps similar to those in steps one through four of Example 39, replacing compound 81B in step one with raw material I in the table below, and employing methods and steps similar to those in Example 41 in step five, compounds 120-125 corresponding to those in the table can be synthesized.
[0589]
[0590]
[0591]
[0592] Example 44
[0593] Using a method and steps similar to those in Example 39, replacing compound 81B in the first step with raw material I in the table below, and replacing 60E in the third step with raw material J in the table below, compounds 126-154 corresponding to those in the table below can be synthesized.
[0594]
[0595]
[0596]
[0597]
[0598]
[0599]
[0600]
[0601]
[0602]
[0603]
[0604]
[0605]
[0606]
[0607]
[0608]
[0609] Example 45
[0610] Following a similar method and steps as in Example 39, compounds 81B in the first step were synthesized by replacing compound 81B in the first step with raw material I in the table below, and by replacing 1G in the second step with raw material K in the table below. The corresponding compounds 156-159 in the table below were synthesized.
[0611]
[0612]
[0613] The synthetic route of compound 158A is as follows:
[0614]
[0615] Following a similar synthetic procedure to compound 1G in Example 1, in step one, compound 1C was replaced with compound 158B, and compound 1D was replaced with compound 158C. The reaction solvent was replaced with N,N-dimethylformamide, and the reaction temperature was increased to 130 degrees Celsius for 12 hours. Compound 158A was then synthesized through a similar step two. MS (ESI+) m / z = 342.0 [M+H].
[0616] 1 H NMR (400 MHz, DMSO-d6) δ = 7.66 (t, J = 7.6 Hz, 1H), 7.36 - 7.24(m, 2H), 7.09 (d, J = 8.0 Hz, 1H), 6.92 (d, J = 7.2 Hz, 1H), 6.69 (d, J = 8.0Hz, 1H), 3.70 (s, 3H), 2.26 (s, 3H), 1.31 (s, 12H).
[0617] The synthetic route for compound 159A is as follows:
[0618]
[0619] Using a similar synthetic procedure to that of compound 1G in Example 1, but replacing compound 1D with compound 159B in step one, compound 159A can be synthesized. MS (ESI+) m / z = 234.9 [M+H].
[0620] 1H NMR (400 MHz, DMSO-d6) δ = 8.66 (d, J = 4.8 Hz, 2H), 7.55 (d, J =8.0 Hz, 1H), 7.51 (d, J = 11.2 Hz, 1H), 7.41 (t, J = 7.2 Hz, 1H), 7.32 (t, J= 4.8 Hz, 1H), 1.31 (s, 12H).
[0621] Example 46
[0622] (2S)-1-(4-(4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)cyclohex-3-ene-1-carbonyl)pyrrolidine-2-carboxynitrile (162)
[0623]
[0624] Following the synthetic route and method of Example 39, 81B was replaced with 162A and 1G was replaced with 55A to synthesize compound 162F.
[0625] Then, by replacing 55G in Example 17 with compound 162F, compound 162 was synthesized using the synthesis steps and methods in steps five and six of Example 17.
[0626] MS (ESI+) m / z = 544.3 [M+H].
[0627] 1H NMR (400 MHz, DMSO-d6) δ 9.01 (s, 1H), 7.74 - 7.72 (m, 2H), 7.44 -7.43 (m, 1H), 6.89 - 6.76 (m, 1H), 6.18 - 6.13 (m, 1H), 5.76 - 5.68 (m, 2H),4.77 - 4.72 (m, 1H), 4.60 - 4.41 (m, 3H), 4.16 - 4.12 (m, 1H), 3.91 - 3.87(m, 1H), 3.79 (s, 3H), 3.74 - 3.70 (m, 2H), 3.62 - 3.55 (m, 2H), 2.77 - 2.58(m, 2H), 2.32 - 2.26 (m, 3H), 2.21 - 2.15 (m, 2H), 2.05 - 1.91 (m, 5H), 1.16- 1.09 (m, 3H), 1.04 - 0.96 (m, 3H).
[0628] Example 47
[0629] (R)-4-Acryloyl-1-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-5-methylpiperazin-2-one (163)
[0630]
[0631] Step 1: (R)-4-(5-bromo-2-chloropyrimidin-4-yl)-2-methyl-5-carbonylpiperazine-1-carboxylic acid tert-butyl ester (163B)
[0632] Compound 163A (84 mg, 0.4 mmol) was dissolved in 3 mL of dioxane, and sodium hydride (32 mg, 60%, 0.8 mmol) was added with stirring at 0°C. The resulting mixture was stirred at 0°C for 30 min, and then 2,4-dichloro-5-bromopyrimidine 81A (123 mg, 0.5 mmol) was added. Stirring was continued at 0°C for 1 h. The reaction mixture was quenched with 1 mL of saturated ammonium chloride solution, followed by the addition of 20 mL of saturated sodium chloride solution and extraction three times with 20 mL of ethyl acetate. The resulting organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 10 / 1-1 / 2) to give compound 163B (89 mg, yield: 55%).
[0633] MS (ESI+) m / z = 405.0, 407.0 [M+H].
[0634] Compound 163 was synthesized by replacing 81C with compound 163B, using experimental methods and steps similar to those in steps two through five of Example 39.
[0635] MS (ESI+) m / z = 544.2 [M+H].
[0636] 1 H NMR (400 MHz, DMSO-d6) δ 9.83 (s, 1H), 8.54 – 8.45 (m, 2H), 7.87(s, 1H), 7.54 (s, 1H), 7.35 (d, J = 11.6 Hz, 1H), 7.28 (s, 1H), 7.19 (d, J =5.0 Hz, 2H), 6.72 (d, J = 64.7 Hz, 1H), 5.65 (s, 1H), 4.73 (d, J = 57.0 Hz, 1H), 4.20 (d, J = 84.4 Hz, 3H), 3.86 – 3.78 (m, 3H), 3.70 (t, J = 20.6 Hz,1H), 2.42 (s, 3H), 1.22 (s, 4H).
[0637] Example 48
[0638] 1-(4-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)prop-2-en-1-one (164)
[0639]
[0640] Step 1: 4-(2-chloro-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (164B)
[0641] Compound 60B (0.35 g, 1.0 mmol), compound 164A (0.40 g, 1.3 mmol), potassium carbonate (0.34 g, 2.4 mmol), and (diphenylphosphine ferrocene)palladium dichloride (70 mg, 0.10 mmol) were added to a mixed solvent of dioxane (5 mL) and water (0.5 mL). After purging with nitrogen three times, the mixture was stirred at 100 °C for 2 hours. The reaction solution was quenched with 10 mL of ammonium chloride and then extracted with 20 mL of ethyl acetate. The resulting organic phase was concentrated to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1-1 / 1) to obtain compound 164B (270 mg, yield: 54%).
[0642] MS (ESI+) m / z = 498.2 [M+H].
[0643] By replacing 81D with compound 164B and employing experimental methods and steps similar to those in steps three through five of Example 39, compound 164 can be synthesized.
[0644] MS (ESI+) m / z = 513.2 [M+H].
[0645] 1 H NMR (400 MHz, DMSO-d6) δ 9.65 (s, 1H), 8.49 (d, J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.88 (s, 1H), 7.53 (s, 1H), 7.39 (t, J = 8.3 Hz, 2H), 7.30 –7.14 (m, 2H), 6.86 (dd, J = 16.6, 10.4 Hz, 1H), 6.12 (dd, J = 16.6, 2.4 Hz, 1H), 5.86 (s, 1H), 5.68 (d, J = 10.4 Hz, 1H), 4.16 – 3.97 (m, 2H), 3.82 (s, 3H), 3.66 (s, 2H), 2.48 – 2.29 (m, 5H).
[0646] Example 49
[0647] Using a similar method and steps as in the synthesis of compound 164, replacing 164A in the first step with raw material L from the table below, compounds 165-166 corresponding to those in the table below were synthesized.
[0648]
[0649] Example 50
[0650] N-(3-(2-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)phenyl)acryloylamide (167)
[0651]
[0652] Step 1: 3-(2-chloro-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)aniline (167B)
[0653] Compound 60B (3.0 g, 8.5 mmol), compound 167A (1.9 g, 8.5 mmol), and (diphenylphosphine ferrocene)palladium dichloride (0.38 g, 0.51 mmol), potassium carbonate (2.4 g, 17 mmol) were dissolved in dioxane (35 mL) and water (3.5 mL). The resulting mixture was reacted at 100 °C under nitrogen atmosphere for 2 hours, and then concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4 / 1-2 / 1) to give compound 167B (0.40 g, 0.98 mmol, yield: 11%).
[0654] MS (ESI+) m / z = 407.9 [M+H].
[0655] Step 2: 4-(3-aminophenyl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-2-amine (167C)
[0656] Compound 167B (0.4 g, 0.98 mmol) was placed in a pressure-resistant reaction tube, and a methanol solution of ammonia (7 mol / L, 6 mL) was added. The resulting solution was reacted under sealed stirring at 60°C for 16 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1-1 / 2) to give compound 167C (0.11 g, 0.28 mmol, yield: 29%).
[0657] MS (ESI+) m / z = 389.2[M+ H].
[0658] Step 3: N-(3-(2-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)phenyl)acryloylamide (167)
[0659] Compound 167C (0.10 g, 0.26 mmol) was dissolved in dichloromethane (3 mL), and triethylamine (78 mg, 0.77 mmol) was added. Acryloyl chloride (19 mg, 0.21 mmol) was added at 0 °C. The reaction was stirred at 0 °C for 1 hour. The reaction solution was concentrated, and the crude product was purified by preparative high performance liquid chromatography (mobile phase: 25%–55% aqueous acetonitrile solution (containing 0.1% formic acid)) to give solid compound 167 (17 mg, yield: 15%).
[0660] MS (ESI+) m / z = 443.0[M+H].
[0661] 1 H NMR (400 MHz, DMSO-d6) δ 10.20 (s, 1H), 8.45 (d, J = 5.2 Hz, 1H), 8.36 (s, 1H), 7.83 (s, 1H), 7.72 - 7.66 (m, 1H), 7.23 (dt, J = 8.2, 6.4 Hz,2H), 7.19 - 7.11 (m, 2H), 6.98 - 6.85 (m, 4H), 6.47 - 6.38 (m, 1H), 6.29 -6.20 (m, 1H), 5.78 - 5.72 (m, 1H), 2.40 (s, 3H).
[0662] Example 51
[0663] N-(3-(2-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)-2-methylphenyl)acryloylamide (168)
[0664]
[0665] Using a similar synthesis method and steps as in Example 50, compound 168 was synthesized by replacing compound 167A with compound 168A.
[0666] MS (ESI+) m / z = 457.0 [M+H].
[0667] 1H NMR (400 MHz, DMSO-d6) δ 9.49 (s, 1H), 8.46 (d, J = 5.2 Hz, 1H), 8.33 (s, 1H), 7.72 ( s, 1H), 7.26 (t, J = 8.4 Hz, 1H), 7.21 - 7.09 (m, 3H), 6.96 (d, J = 8.2 Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 6.87 (s, 2H), 6.52 (dd,J = 17.6, 10.4 Hz, 1H), 6.23 (dd, J = 16.8,1.6 Hz, 1H), 5.74 (d, J = 9.6 Hz,1H), 2.41 (s, 3H), 2.20 (s, 3H).
[0668] Example 52
[0669] N-(3-(2-hydroxy-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)phenyl)acryloylamide (169)
[0670]
[0671] Using a synthesis method and steps similar to those in steps two and three of Example 50, compound 169 was synthesized by replacing the 7 mol / L methanol solution of ammonia with a 1.0 mol / L sodium hydroxide solution of dioxane / water (1 / 1, v / v).
[0672] MS (ESI+) m / z = 444.1[M+H].
[0673] Example 53
[0674] Following the same methods and steps as in steps one through four of Example 39, replacing compound 81B in step one with raw material I in the table below, and then using the same methods and steps as in Example 41 in step five, replacing compound 63A with raw material M in the table below, compounds 170-174 corresponding to those in the table can be synthesized.
[0675]
[0676]
[0677] Example 54
[0678] 2-Fluoro-N-(5-(5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)pyridin-3-yl)acryloylamide (181)
[0679]
[0680] Step 1: 5-(2-chloro-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)pyrimidin-4-yl)pyridine-3-amine (181B)
[0681] Compound 60B (1.5 g, 4.3 mmol), compound 181A (0.94 g, 4.3 mmol), potassium carbonate (2.2 g, 17 mmol), and (diphenylphosphine ferrocene)palladium dichloride (0.62 g, 0.85 mmol) were mixed in 1,4-dioxane (20 mL) and water (2 mL). The resulting mixture was stirred at 100°C for 2 hours under a nitrogen atmosphere. After cooling to room temperature, water (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (100 mL × 3). The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was subjected to preparative high-performance liquid chromatography (Waters Xbridge C18, 20-60% acetonitrile aqueous solution (containing 0.01% ammonia)) to obtain compound 181B (0.67 g, yield: 38%).
[0682] MS (ESI+) m / z = 409.1[M+H]
[0683] Step 2: 4-(5-aminopyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (181C)
[0684] Compound 118B (0.52 g, 1.3 mmol), compound 60E (0.24 g, 2.5 mmol), and p-toluenesulfonic acid (0.22 g, 1.3 mmol) were dissolved in N-methylpyrrolidone (4 mL). The resulting mixture was stirred in a microwave at 140°C for 1 hour. After cooling to room temperature, water (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (100 mL × 3). The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was subjected to preparative high-performance liquid chromatography (Waters Xbridge C18, 20-60% acetonitrile aqueous solution (containing 0.01% ammonia)) to obtain compound 181C (67 mg, yield 11%).
[0685] MS (ESI+) m / z = 470.3[M+1].
[0686] Step 3: 2-Fluoro-N-(5-(5-(3-Fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)pyridin-3-yl)acryloylamide (181)
[0687] Compound 181C (10 mg, 0.021 mmol) was dissolved in dichloromethane (2 mL), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (16 mg, 0.042 mmol), compound 63A (1.9 mg, 0.021 mmol), and N,N-diisopropylethylamine (8.1 mg, 0.063 mmol) were added. The resulting mixture was stirred at room temperature for 1 hour. The solvent was removed by vacuum distillation, and the crude product was purified by preparative high-performance liquid chromatography (Waters Xbridge C18, 20-60% acetonitrile aqueous solution (containing 0.01% ammonia)) to obtain compound 181 (2.4 mg, yield: 21%).
[0688] MS (ESI+) m / z = 542.2[M+H].
[0689] 1H NMR (400 MHz, DMSO-d6) δ 10.70 (s, 1H), 9.86 (s, 1H), 8.82 (s, 1H), 8.80 - 8.61 (m, 1H), 8.58 (s, 1H), 8.46 (d, J = 5.2 Hz, 1H), 8.15 (s, 1H),8.06 (s, 1H), 7.54 (s, 1H), 7.38 - 7.26 (m, 2H), 7.19 (d, J = 5.2 Hz, 1H),7.06 (d, J = 6.4 Hz, 1H), 5.85 - 5.68 (m, 1H), 5.51 (dd, J = 15.2, 3.6 Hz, 1H), 3.84 (s, 3H), 2.42 (s, 3H).
[0690] Biological evaluation
[0691] The following description and explanation of this application are combined with test examples, but these embodiments are not intended to limit the scope of this application.
[0692] Test Example 1: FGFR enzyme inhibition experiment of the compound of the present invention
[0693] The control positive compound BGJ398 used in the experiment was purchased from Selleck (catalog number S2183). The test compound sample was dissolved in DMSO to prepare a 10 mM stock solution, which was stored at -30°C.
[0694] Enzyme reactions were performed using enzyme reaction kits manufactured by Promega (FGFR1 Kit, catalog number V2991; FGFR2 kit, catalog number V4060; FGFR3 kit, catalog number VA7459; substrate: Poly E4Y1) according to the manufacturer's recommended methods. The reaction products were detected using the ADP assay kit manufactured by Promega (ADP-Glo™ Kinase Assay, catalog number V9101).
[0695] The 5 μL reaction system contained 0.4 ng / μL FGFR1 kinase (or 1.4 ng / μL FGFR2 (WT (wild-type) or V564F mutant) kinase, or 1 ng / μL FGFR3 kinase), 0.2 μg / μL Poly E4Y1, 5 μM ATP, and serially diluted test compounds. The final concentration of DMSO in the reaction system was 1%. The reaction was performed in 384-well plates (Perkinelmer, Cat. 6007290), with all assays performed in duplicate. ATP was added last to initiate the reaction in the above system. The 384-well plate was incubated at 25°C for 60 minutes, then 5 μL of ADP-Glo was added, and the reaction was incubated at 25°C for 40 minutes. Finally, 10 μL of detection buffer was added, and the reaction was incubated at 25°C for 30 minutes. Luminescence was measured using Perkinelmer Envision after the reaction. Luminescence values represent the amount of ADP produced. The inhibition rate of kinase activity is calculated using high signal (Luminescence value with enzyme but no inhibitor), low signal (Luminescence value without enzyme), and sample signal (Luminescence value with both enzyme and inhibitor). The half-maximal inhibitory concentration (IC50) is calculated using XLfit 2.0 software (ID Business Solutions Ltd). 50 ).
[0696] Inhibition rate % = (high signal -sample signal) / (high signal -low signal)×100%.
[0697] The in vitro activity of the compounds in this invention against wild-type FGFR2 enzyme was determined by the above experiments, and the measured IC50 values were... 50 The values are shown in Table 1.
[0698] Table 1
[0699]
[0700] The in vitro activity of the compounds in this invention against the V564F mutant FGFR2 enzyme was determined by the above experiments, and the measured IC50 values were... 50 The values are shown in Table 2.
[0701] Table 2
[0702]
[0703] Test Example 2: Cell proliferation experiment of the compound of the present invention
[0704] The test compound sample was dissolved in DMSO to prepare a 10 mM stock solution, which was stored at -30°C. For assay, the compound was diluted 10 times to the assay concentration in serum-free medium containing 5% DMSO.
[0705] In the experiment, SNU-16 cells were purchased from ATCC (American Type Culture Collection, USA, catalog number ATCC® CRL-5974), RT-112 cells from Cobioer (Nanjing Kebai Biotechnology Co., Ltd., catalog number CBP60316), KG-1 cells from ATCC (catalog number CCL-246), and JMSU-1 cells from DSMZ (catalog number ACC505). IMDM culture medium was purchased from Gibco (catalog number 12440-061), 1640 culture medium from Gibco (catalog number 12634-010), and serum from Gibco (catalog number 10099-141C). Cell-counting kit-8 (CK04) was purchased from Tongren Chemical Co., Ltd. CellTiter-Glo® Luminescent Cell Viability Assay was purchased from Promega (catalog number G7570).
[0706] Cells in logarithmic growth phase were seeded in 96-well cell culture plates at a volume of 100 µL. Incubation was carried out overnight at 37°C with 5% CO2. The next day, 10 µL / well of serially diluted test compound was added. For the control group, 10 µL / well of serum-free medium containing 5% DMSO was added instead of the drug dilution solution; the final DMSO concentration was 0.5%. Incubation was continued for 72 hours. 10 µL / well of Cell-counting kit-8 reagent (or 50 µL / well of CTG) was added. Incubation was carried out at 37°C for 40 minutes in a CO2 incubator, and absorbance was read at 450 nm (Luminescence for CTG). The inhibitory rate of the compound on cell growth was calculated using the following formula, and the half-maximal inhibitory concentration (GI) was calculated using XLFit 2.0 software. 50 ).
[0707] Inhibition rate (%) = [1 - ([OD 450 ] 化合物 - [OD 450 ] 背景 ) / ([OD 450 ] 细胞 - [OD 450 ] 背景)] ×100%
[0708] in:
[0709] [OD 450 ] 化合物 The optical density value represents the amount of light passing through the pores treated with the compound.
[0710] [OD 450 ] 细胞 The optical density value of the cell pores on day 3 when DMSO was used instead of the compound;
[0711] [OD 450 ] 背景 The optical density value of the cell pores on day 0 when DMSO was used instead of the compound;
[0712] The compounds in this invention were tested in cell proliferation experiments using the methods described above, and the measured GI values were obtained. 50 The values are shown in Table 3.
[0713] Table 3
[0714]
[0715]
[0716] "-" indicates that it has not been tested.
[0717] Test Example 3: Blood Stability Test of the Compounds of the Present Invention
[0718] The stability of the compounds of the present invention in whole blood was assessed by determining the remaining percentage of the test compound in the blood (containing EDTA-K2 anticoagulant) of SD rats or humans at different time points using liquid chromatography-tandem mass spectrometry (LC / MS / MS).
[0719] Add 398 μL of blood to the wells of a culture plate and pretreat at 37°C for 15 min. Add 2 μL of the test compound (1 mmol / L DMSO solution) or positive compound (1 mmol / L DMSO solution) to the pretreated 398 μL of blood and mix to a final concentration of 5 µM for the test compound (or positive compound) and 0.5% for the organic solvent. Perform two tests for each test compound or positive compound. Incubate the resulting mixture at 37°C. At 0, 15, 30, 60, 120, and 240 minutes of the reaction, take 50 μL of sample and add 50 µL of ultrapure water and 400 µL of cold acetonitrile containing the internal standard compound (0.5 μM tolbutamide) to terminate the reaction. Vortex all samples for 10 min and centrifuge at 3220 g for 30 min to precipitate the protein. Perform LC-MS / MS analysis on 200 μL of the supernatant.
[0720] All calculations were performed using Microsoft Excel. Peak area ratios were determined from the extracted ion chromatograms. The percentage of remaining compounds at each time point was calculated using the following formula:
[0721] Remaining percentage t min (%) = Peak area ratio t min / peak area ratio 0 min x 100%
[0722] Peak area ratio t min This represents the peak area ratio of the tested compound (or positive compound) and the internal standard compound at time point t minutes.
[0723] Peak area ratio 0 min This represents the peak area ratio of the tested compound (or positive compound) to the internal standard compound at the 0-minute time point.
[0724] The slope value k was determined by linear regression of the natural logarithm of the curve of the remaining percentage of the tested compound versus the incubation time.
[0725] in vitro half-life (t) 1 / 2 Determined by the slope value k:
[0726]
[0727] The half-lives of the compounds of this invention in SD rat or human blood are shown in Table 4.
[0728] Table 4. Stability of the compounds of the present invention in SD rats and human blood.
[0729]
[0730] "-" indicates that it has not been tested.
[0731] Test Example 4: CYP Enzyme Inhibition Test of the Compounds of the Present Invention
[0732] The representative substrate metabolism responses of the five major human CYP subtypes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) were evaluated using a mixture of 150 donor human liver microsomes (purchased from Corning, catalog number 452117). The effects of different concentrations of the analytes on the metabolic responses of phenacetin (CYP1A2), diclofenac sodium (CYP2C9), S-metphenytoin (CYP2C19), bufrolol hydrochloride (CYP2D6), and midazolam (CYP3A4) were determined by liquid chromatography-tandem mass spectrometry (LC / MS / MS).
[0733] A 200 μL reaction mixture (100 mmol / L phosphate buffer, pH 7.4, containing 0.3% DMSO, 0.6% acetonitrile, and 0.1% methanol, by volume) of 30 μM phenacetin, 10 μM diclofenac sodium, 35 μM S-mphenanthridine, 5 μM buturolol hydrochloride, 3 μM midazolam, 1 mM reduced nicotinamide adenine dinucleotide phosphate (NADPH), the test compound (concentrations of 0.1, 0.3, 1, 3, 10, and 30 μmol / L, respectively), the positive compound, or the blank control, and mixed human liver microsomes (0.2 mg / mL) was incubated at 37 °C for 5 min. Then, 200 μL of acetonitrile solution containing 3% formic acid and 40 nM internal standard verapamil was added, and the mixture was centrifuged at 4000 rpm for 50 min. The mixture was cooled on ice for 20 min, and then centrifuged at 4000 rpm for 20 min to precipitate the protein. Take 200 μL of the supernatant for LC-MS / MS analysis.
[0734] Peak area is calculated from the chromatogram. Residual activity percentage (%) is calculated using the following formula:
[0735] Peak area ratio = Metabolite peak area / Internal standard peak area
[0736] Residual activity percentage (%) = Peak area percentage of the test compound group / Peak area percentage of the blank group
[0737] CYP half-maximal inhibitory concentration (IC50) 50 This was calculated using Excel XLfit 5.3.1.3.
[0738] The CYP half-maximal inhibitory concentration (IC50) of the compound of this invention was measured. 50 The values are shown in Table 5.
[0739] Table 5. Half-maximal inhibitory concentration (IC50) of the compounds of this invention against CYP 50 )
[0740]
[0741] Test Example 5: Caco-2 Permeability Experiment
[0742] The apparent permeability (Pp) of the drug was determined using liquid chromatography-tandem mass spectrometry (LC-MS / MS) in a Caco-2 cell model. app ).
[0743] In this test case, Caco-2 cells were purchased from the American Type Culture Collection (ATCC), HEPES from Beijing Solarbio Science & Technology Co., Ltd., Hank's Balanced Salt Solution (HBSS) and Non-essential Amino Acids (NEAA) from Thermo Fisher Scientific, penicillin, streptomycin, and trypsin / EDTA from Solarbio, fetal bovine serum (FBS) and DMEM medium from Corning, HTS-96-well Transwell plates and other sterile consumables from Corning, the Millicell electrical resistance measurement system from Millipore, and Cellometer. ® The K2 was purchased from Nexcelom Bioscience, the Infinite 200 PRO microplate reader was purchased from Tecan, and the MTS2 / 4 orbital shaker was purchased from IKA Labortechnik.
[0744] Step 1: Cell Culture and Seeding
[0745] Caco-2 cells were cultured in cell culture flasks. The incubator was set to 37°C, 5% CO2, and 95% relative humidity. Cells were ready for Transwell inoculation when confluence reached 70-90%. Before inoculation, 50 μL of cell culture medium was added to each well in the upper chamber of the Transwell, and 25 mL of cell culture medium was added to the lower culture plate. The culture plate was incubated at 37°C, 5% CO2 for 1 hour before inoculation. After cell digestion, the cell suspension was transferred to a round-bottom centrifuge tube and centrifuged at 120 g for 5 minutes. The cells were resuspended in culture medium to a final concentration of 6.86 × 10⁻⁶. 5 cells / mL. Add 50 μL of cell suspension to each well of a 96-well Transwell plate, resulting in a final seeding density of 2.4 × 10⁶ cells / mL. 5 cells / cm². Medium changes should begin 24 hours after inoculation. Culture for 14-18 days, changing the medium every other day. The medium change procedure is as follows: Separate the Transwell chambers from the receiving plate. First discard the medium in the receiving plate, then discard the medium in the Transwell chambers. Finally, add 75 μL of fresh medium to each chamber and 25 mL of fresh medium to the receiving plate.
[0746] The second step is the evaluation of the integrity of the cell monolayer.
[0747] After approximately 14 days of culture, Caco-2 cells reach convergence and complete differentiation. At this point, they can be used for breakthrough experiments. The monolayer membrane resistance is measured using a resistance meter (Millipore, USA), and the resistance of each well is recorded. After the measurement, the Transwell plate is returned to the incubator. The resistance value is calculated as: measured resistance (ohms) × membrane area (cm²). 2 = TEER value (ohm∙cm) 2 If the TEER value is < 230 ohms∙cm 2 If so, the hole cannot be used for a penetration test.
[0748] Step 3: Solution Preparation
[0749] Weigh out 2.38 g HEPES and 0.35 g sodium bicarbonate, add 900 mL of pure water to dissolve them, then add 100 mL of 10×HBSS and stir well. Adjust the pH to 7.4, and finally filter to obtain 1 L of transfer buffer (HBSS, 10 mM HEPES, pH 7.4).
[0750] A 1 mM DMSO stock solution of the test compound was diluted with transfer buffer to obtain a 5 μM test solution. The control compound digoxin or minoxidil was diluted to 2 mM with DMSO and then to 10 μM with the same transfer buffer to obtain a control compound test solution. Additionally, DMSO was also diluted with the same transfer buffer to a receiving end solution containing 0.5% DMSO.
[0751] Step 4 Drug Penetration Test
[0752] Remove the Transwell culture plate from the incubator. Rinse the cell monolayer twice with transport buffer (10 mM HEPES, pH 7.4) and incubate at 37°C for 30 minutes.
[0753] The transport rate of the compound from the top to the base was determined. 125 μL of test solution was added to each well in the upper chamber (top), and immediately 50 μL of the solution was transferred from the top to 200 μL of acetonitrile (0.1 μM tolbutamide) containing the internal standard as the initial sample from the top to the base. 235 μL of receiving end solution was added to each well in the lower chamber (base).
[0754] The transport rate of the compound from the base to the top was determined. 285 μL of the receiving end solution was added to each well in the upper chamber (top), and immediately 50 μL of the solution was transferred from the top to 200 μL of acetonitrile (0.1 μM tolbutamide) containing the internal standard as the initial sample from base to top. 75 μL of the test solution was added to each well in the lower chamber (base).
[0755] After merging the upper and lower transfer devices, incubate at 37 °C for 2 hours.
[0756] After incubation, 50 μL of sample was taken from each well of the upper and lower chambers of the Transwell plate and added to a new sample tube. 200 μL of acetonitrile (0.1 μM tolbutamide) containing the internal standard was added to the sample tube, vortexed for 10 minutes, and then centrifuged at 3220 g for 40 minutes. 150 μL of the supernatant was collected, diluted with 150 μL of water, and analyzed by LC-MS / MS. All samples were prepared in triplicate.
[0757] The integrity of the cell monolayer was assessed by fluorescein leakage after 2 hours of incubation. Fluorescein stock solution was diluted to a final concentration of 100 μM using transport buffer (10 mM HEPES, pH 7.4). 100 μL of fluorescein solution was added to each well of the upper Transwell plate, and 300 μL of transport buffer (10 mM HEPES, pH 7.4) was added to each well of the lower receiving plate. After incubation at 37°C for 30 minutes, 80 μL of solution was aspirated from both the upper and lower layers of each well into a new 96-well plate. Fluorescence was measured using a microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.
[0758] Step 5: Data Analysis. All calculations were performed using Microsoft Excel. Peak areas were determined using the extracted ion chromatograms.
[0759] Apparent permeability coefficient (P) app Unit: cm / s × 10 -6 The following formula can be used to calculate:
[0760]
[0761] In the formula: V A The volume of the receiving solution is given (Ap→Bl is 0.3 mL, Bl→Ap is 0.1 mL), and the area (membrane area) is the membrane area of the Transwell-96-well plate (0.143 cm²). 2 ); time (incubation time, in seconds); [drug] receiver ([drug] 接收端 () represents the drug concentration at the receiving end; [drug] initial,donor ([drug] 初始,供体 () represents the initial drug concentration at the dosing end.
[0762] The efflux ratio is calculated using the following formula:
[0763]
[0764] In the formula: P app (B-A) The apparent permeability coefficient is measured from the base to the tip.
[0765] P app (A-B) The apparent permeability coefficient is calculated from the top to the base.
[0766] The recovery rate ("Percentage recovery" (%)) is calculated using the following formula:
[0767] %
[0768] In the formula: V A V represents the volume of the solution at the receiving end (unit: mL); D The volume of solution at the donor end (in mL) is [drug]. donor ([drug] 供体 () represents the drug concentration at the dosing end.
[0769] The leakage rate (Percentage leakage (%) or LY (%)) is calculated using the following formula:
[0770] %
[0771] In the formula: I receiver (I) 接收端 ) refers to the fluorescence density of the receiving aperture (0.3 mL), I donor (I) 供体 LY refers to the fluorescence density of the drug-dosing well (0.1 mL). LY < 1.5% indicates an intact monolayer cell membrane. For individual cases where LY > 1.5%, if P app The values are similar to other parallel values, and based on scientific judgment, the final data can be adopted.
[0772] The Caco2 permeability data obtained from testing the compounds of this invention are shown in Table 6 below.
[0773] Table 6. Caco2 permeability data of the compounds of the present invention
[0774]
[0775] Test Example 6: In vivo pharmacokinetic test of the compound of the present invention in rats
[0776] Using SD rats as test animals, the plasma drug concentrations at different time points after intravenous injection and gavage administration of the compound of the present invention were determined by LC / MS / MS. The pharmacokinetic behavior of the compound of the present invention in rats was studied, and its pharmacokinetic characteristics were evaluated.
[0777] Three healthy male SD rats aged 6-8 weeks were included in each group.
[0778] Intravenous administration: Weigh a certain amount of the drug, add 10% volume of N,N-dimethylacetamide, 33% volume of triethylene glycol and 57% volume of physiological saline to prepare a colorless, clear and transparent liquid at 1 mg / mL.
[0779] Gavage administration: Weigh a certain amount of the drug, add 0.5% by mass of hydroxypropyl methylcellulose, 0.1% by volume of Tween 80 and 99.6% by volume of physiological saline to prepare a white suspension of 1 mg / mL.
[0780] After fasting overnight, SD rats were administered the drug via intravenous injection or gavage.
[0781] The compound of the present invention was administered to rats via intravenous injection. 0.2 mL of blood was collected from the jugular vein at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 hours after administration. The blood was placed in a test tube containing EDTA-K2, centrifuged at 4000 rpm for 5 minutes at 4°C to separate the plasma, and stored at -75°C.
[0782] Alternatively, rats may be administered the compound of the present invention by gavage. 0.2 mL of blood may be collected from the jugular vein at 0.25, 0.5, 1, 2, 4, 8, and 24 hours after administration. The blood may be placed in a test tube containing EDTA-K2, centrifuged at 3500 rpm for 10 minutes at 4°C to separate the plasma, and stored at -75°C.
[0783] To determine the content of the target compound in rat plasma after intravenous injection or gavage administration of different concentrations of the drug: Take 30 μL of rat plasma at each time point after administration, add 200 μL (50 ng / mL) of acetonitrile solution of internal standard dexamethasone, vortex mix for 30 seconds, centrifuge at 4700 rpm for 15 minutes at 4℃, take the supernatant of the plasma sample, dilute it three times with water, and take 2.0 μL for LC-MS / MS analysis.
[0784] The pharmacokinetic parameters of the compounds of this invention in rats are shown in Table 7 below:
[0785] Table 7. Pharmacokinetic results of the compounds of the present invention in SD rats.
[0786]
[0787]
[0788] IV indicates intravenous administration; PO indicates oral administration.
Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt, (I) X is selected from CR 9 Or N; Z is selected from CR 9 ; W is selected from O or C (=O); Y is selected from C(=O), NHC(=O), C(=O)NH, N(CH3) or bonds; Ring A is selected from 5-10 membered heteroaryl or 5-10 membered heterocyclic group; Ring B is selected from C6-C 10 Aryl, 5-10 heteroaryl or C3-C 10 Cyclic hydrocarbon group; E is selected from C3-C 10 Cyclic hydrocarbon group, C6-C 10 Aryl, 3-12-membered heterocyclic or 5-12-membered heteroaryl, wherein the C3-C 10 Cyclic hydrocarbon C6-C 10 Aryl, 3-12 heterocyclic or 5-12 heteroaryl, optionally bound by one or more R 1a replace; R 1a Independently selected from halogens, CN, NH2, OH, C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, C1-C6 alkoxy, -S(=O)-C1-C4 alkyl, -S(=O)2-C1-C4 alkyl, -S(=O)(=NR) 8a )R 8b -N=S(=O)R 8a R 8b -NR 8a R 8b -C(=O)NR 8a R 8b or -NR 7 C(=O)R 8b The C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, C1-C6 alkoxy, -S(=O)-C1-C4 alkyl or -S(=O)2-C1-C4 alkyl may optionally be substituted by one or more groups independently selected from halogen, OH, C1-C3 alkoxy or CN; R 1 is selected from -C≡CR 5 , -C(=O)C≡CR 5 , -C(=O)CR 6 =C(R 5 )2, - R 7 C(=O)CH=C(R 5 )2, -NHC(=O)CR 6 =C(R 5 )2, -R 7 NHC(=O)CH=C(R 5 )2, -NHC(=O)C≡CR 5 , -S(=O)CR 6 =C(R 5 )2, -S(=O)2CR 6 =C(R 5 )2, -NHS(=O)CR 6 =C(R 5 )2, -NHS(=O)2CR 6 =C(R 5 )2, -NR 6 C(=O)CR 6 =C(R 5 )2 or NHC(=O)R 5 ; R 5 Independently selected from H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cyclic hydrocarbon, 3-12 membered heterocyclic group or C6-C 10 aryl, wherein the C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cyclic hydrocarbon, 3-12 membered heterocyclic group or C6-C 10 The aryl group is optionally bounded by one or more R groups. 5a replace; R 5a Independently selected from halogens, CN, N(R) 5b 2, OH, NO2, C3-C8 cycloalkyl or 3-12 membered heterocyclic groups; R 5b Independently selected from H or C1-C6 alkyl groups; R 6 Selected from H, CN, halogens, or C1-C6 alkyl groups; R 7 Selected from C1-C6 alkylene groups, C3-C8 cycloalkylene groups, or 3-12 membered heterocyclic groups; R 2 Selected from H, NH2, C1-C6 alkyl, OH or halogen; R 3 It is independently selected from halogens, CN, NH2, OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy or C3-8 cycloalkyl; R 4 Independently selected from halogens, CN, NH2, OH, NO2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3-10 membered heterocyclic groups, -C(=O)R 8a -C(=O)OR 8a -NR 8a R 8b -C(=O)NR 8a R 8b or -NR 7 C(=O) R 8b The C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or 3-10 membered heterocyclic group is optionally surrounded by one or more R groups. 4a replace; R 4a Independently selected from halogens, CN, NH2, OH, or C1-C6 alkyl groups; R 8a R 8b Each is independently selected from H, halogen, CN, NH2, OH, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkyl; R 9 Selected from H, CN, OH, NH2, -NHR 10 -NH-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy or C3-C8 cycloalkyl, wherein the C1-C6 alkyl, -NH-C1-C6 alkyl, C1-C6 alkoxy or C3-C8 cycloalkyl is optionally surrounded by one or more R 10 replace; R 10 Independently selected from halogens, NH2, C3-C8 cycloalkyl groups, 3-10 membered heterocyclic groups, C6-C 10 aryl or 5-10 membered heteroaryl, wherein the NH2, C3-C8 cycloalkyl, 3-10 membered heterocyclic, C6-C 10 aryl or 5-10 heteroaryl groups are optionally surrounded by one or more R groups. 11 replace; R 11 Independently selected from C1-C6 alkyl, halogen, C1-C6 alkoxy, C3-C8 cycloalkyl or 3-10 heterocyclic groups, wherein the C1-C6 alkyl, C3-C8 cycloalkyl or 3-10 heterocyclic group is optionally substituted with C1-C6 alkyl, halogen, OH, -NH-C1-C6 alkyl, -N(C1-C6 alkyl)2; n and m are each independently selected from 0, 1, 2 or 3; q is selected from 1, 2, or 3.
2. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: Ring A is selected from 5-6 membered heteroaryl or 5-6 membered heterocyclic group.
3. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: Cycle A is selected from 5-6 heteroaryl groups.
4. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: Ring A is selected from pyrimidinyl, pyridinyl, or tetrahydropyrroleyl.
5. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: Ring B is selected from C6-C 10 Aryl or C3-C 10 Cyclic hydrocarbon group.
6. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1 or 5, characterized in that: Cycle B is selected from phenyl or cyclohexenyl.
7. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: Ring B is selected from phenyl.
8. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: E is selected from C3-C6 cyclic hydrocarbon groups, C6-C 10 aryl, 3-10 membered heterocyclic or 5-10 membered heteroaryl, wherein the C3-C6 cyclic hydrocarbon group, C6-C 10 Aryl, 3-10 heterocyclic or 5-10 heteroaryl are optionally R 1a replace.
9. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1 or 8, characterized in that: E is selected from C6-C 10 Aryl, 3-10 membered heterocyclic or 5-10 membered heteroaryl, wherein the C6-C 10 Aryl, 3-10 heterocyclic or 5-10 heteroaryl are optionally R 1a replace.
10. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 1a Independently selected from halogens, CN, NH2, OH, -NR 8a R 8b The C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, and C1-C6 alkoxy group are optionally substituted by one or more groups independently selected from halogen, OH, or C1-C3 alkoxy groups.
11. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 1a The group is independently selected from halogen, CN, NH2, OH, C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, and C1-C6 alkoxy group, wherein the C1-C6 alkyl, C3-C8 cyclic hydrocarbon, 3-6 membered heterocyclic group, and C1-C6 alkoxy group are optionally substituted by one or more groups independently selected from halogen, OH, or C1-C3 alkoxy group.
12. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 1a Independently selected from halogens, -NR 8a R 8b The C1-C6 alkyl or C1-C6 alkoxy group is optionally substituted with one or more groups independently selected from halogen, OH, CN or C1-C3 alkoxy groups.
13. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 1 is selected from -C≡CR 5 , -C(=O)C≡CR 5 , -C(=O)CR 6 =C(R 5 )2, -R 7 C(=O)CH=C(R 5 )2, -NHC(=O)CR 6 =C(R 5 )2, -R 7 NHC(=O)CH=C(R 5 )2, -NHC(=O)C≡CR 5 , -NHS(=O)2CR 6 =C(R 5 )2, -NR 6 C(=O)CR 6 =C(R 5 )2 or NHC(=O)R 5 .
14. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 1 Selected from the following groups: , , , , , , , , , , , , , , , , , , , , , , , , , , , or .
15. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 2 Selected from H, NH2, CH3, OH or halogens.
16. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 3 It is independently selected from halogens, C1-C6 alkyl groups, C1-C6 alkoxy groups, or C1-C6 haloalkyl groups.
17. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 3 It is independently selected from halogens or C1-C6 alkoxy groups.
18. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, 16 or 17, characterized in that: R 3 Selected from halogens.
19. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: m is selected from 0 or 1.
20. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 4 Independently selected from halogens, CN, NH2, OH, NO2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, and 3-10 heterocyclic groups, wherein the C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, and 3-10 heterocyclic groups are optionally surrounded by one or more R groups. 4a replace.
21. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 4 It is independently selected from CN, halogen, C1-C6 alkyl or C1-C6 alkoxy.
22. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, 20 or 21, characterized in that: R 4 It is independently selected from CN or C1-C6 alkyl groups.
23. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: n is selected from 0 or 1.
24. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 9 Selected from H, CN, OH, NH2, -NHR 10 or -NH-C1-C6 alkyl, wherein the -NH-C1-C6 alkyl is optionally surrounded by one or more R 10 replace.
25. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 9 Selected from H, NH2, -NHR 10 -NH-C1-C6 alkyl or C1-C6 alkyl, wherein the C1-C6 alkyl or -NH-C1-C6 alkyl is optionally substituted with one or more R 10 replace.
26. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: R 9 Selected from the following groups: H, CN, OH, NH2, , , , , , , , , , , , , , , , , , , , , , , or .
27. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: Y is selected from N(CH3) or bond.
28. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: The compound or pharmaceutically acceptable salt represented by formula (I) is selected from the compound or pharmaceutically acceptable salt represented by formula (II). (II).
29. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: The compound or pharmaceutically acceptable salt represented by formula (I) is selected from the compound or pharmaceutically acceptable salt represented by formula (III). (III).
30. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: The compound or pharmaceutically acceptable salt represented by formula (I) is selected from the compound or pharmaceutically acceptable salt represented by formula (IV). (IV).
31. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: The compound or pharmaceutically acceptable salt represented by formula (I) is selected from the compound or pharmaceutically acceptable salt represented by formula (V). (V)。 32. The compound or pharmaceutically acceptable salt of formula (I) according to claim 1, characterized in that: The compound or pharmaceutically acceptable salt represented by formula (I) is selected from the following compounds or pharmaceutically acceptable salts. or .
33. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1-32 or a pharmaceutically acceptable salt, and a pharmaceutically acceptable excipient.
34. Use of the compound or pharmaceutically acceptable salt of formula (I) according to any one of claims 1-32, or the pharmaceutical composition of claim 33, in the preparation of a medicament for the prevention or treatment of diseases related to FGFR.
35. The use according to claim 34, characterized in that: The diseases associated with FGFR are selected from cancer.
Citation Information
Patent Citations
Pyridazine derivatives
CN101535275A
